Anixa Biosciences (ANIX) 10-K 23 Dec 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Oct. 31, 2015	Dec. 17, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ITUS CORPORATION
Document Type	10-K
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		8,724,878
Entity Public Float			$ 23,589,150
Amendment Flag	false
Entity Central Index Key	715,446
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Oct. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Current assets:
Cash and cash equivalents	$ 4,369,219	$ 3,361,246
Short–term investments in certificates of deposit	2,400,000	2,500,000
Accounts receivable		400,000
Prepaid expenses and other current assets	126,528	60,577
Total current assets	6,895,747	6,321,823
Patents, net of accumulated amortization of $639,744 and $314,453, respectively	2,396,367	2,721,658
Property and equipment, net of accumulated depreciation of $13,617 and $48,842, respectively	43,456	11,875
Total assets	9,335,570	9,055,356
Current liabilities:
Accounts payable and accrued expenses	380,765	1,249,426
Royalties and contingent legal fees payable	213,017	560,076
Total current liabilities	593,782	1,809,502
Patent acquisition obligation (Note 7)	3,688,187	3,236,281
Total liabilities	$ 4,281,969	$ 5,045,783
Commitments and contingencies (Notes 7 and 8)
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares issued and outstanding, respectively	$ 14,000	$ 14,000
Common stock, par value $.01 per share; 24,000,000 shares authorized; 8,724,878 and 8,788,176 shares issued and outstanding, respectively	87,249	87,882
Additional paid-in capital	151,101,117	148,677,413
Accumulated deficit	(146,148,765)	(144,769,722)
Total shareholders’ equity	5,053,601	4,009,573
Total liabilities and shareholders’ equity	$ 9,335,570	$ 9,055,356
Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares issued and outstanding, respectively
Total shareholders’ equity	$ 14,000	$ 14,000
Series A Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares issued and outstanding, respectively	$ 14,000	$ 14,000

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Patents, accumulated amortization (in Dollars)	$ 639,744	$ 314,453
Property and equipment, accumulated depreciation (in Dollars)	$ 13,617	$ 48,842
Common stock par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	24,000,000	24,000,000
Common stock, shares issued	8,724,878	8,788,176
Common stock, shares outstanding	8,724,878	8,788,176
Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued
Preferred stock, shares outstanding
Series A Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares issued	140	140
Preferred stock, shares outstanding	140	140

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Revenue:
Revenue from licensing activities	$ 255,000	$ 2,480,000
Amortization of display technology development and license fees received from AU Optronics Corporation in fiscal year 2011		1,187,320
Settlement with AU Optronics Corporation	9,000,000
Total revenue	9,255,000	3,667,320
Operating costs and expenses:
Inventor royalties and contingent legal fees	147,670	1,412,661
Litigation and licensing expenses	3,500,852	575,413
Amortization of patents	325,291	314,453
Marketing, general and administrative expenses (including non-cash stock option compensation expense of $2,676,309 and $3,149,799, respectively)	6,225,946	6,408,861
Total operating costs and expenses	10,199,759	8,711,388
Loss from operations	$ (944,759)	(5,044,068)
Impairment in value of Videocon Industries Limited global depository receipts		(62,825)
Change in value of derivative liability (Note 5)		(592,945)
Loss on extinguishment of debt (Note 5)		(2,699,022)
Interest expense (Notes 5 and 7)	$ (451,906)	(1,263,617)
Dividend income		47,568
Interest income	$ 17,622	8,595
Loss before income taxes	$ (1,379,043)	$ (9,606,314)
Provision for income taxes (Note 8)
Net loss	$ (1,379,043)	$ (9,606,314)
Net loss per share:
Basic and diluted (in Dollars per share)	$ (0.16)	$ (1.10)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	8,760,126	8,710,867

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS (Parentheticals) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Non-cash Stock Option Compensation Expenses	$ 2,676,309	$ 3,149,799

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY - USD ($)	Investment In Videocon [Member]Common Stock [Member]	Investment In Videocon [Member]Additional Paid-in Capital [Member]	Common Stock And Preferred Stock [Member]Preferred Stock [Member]	Common Stock And Preferred Stock [Member]Common Stock [Member]	Common Stock And Preferred Stock [Member]Additional Paid-in Capital [Member]	Common Stock And Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Loan Receivable From Former Affiliate [Member]	Retained Earnings [Member]	Total
BALANCE at Oct. 31, 2013								$ 83,716	$ 136,759,099	$ (5,000,000)	$ (135,163,408)	$ (3,320,593)
BALANCE (in Shares) at Oct. 31, 2013								8,371,558
Stock option compensation to employees and consultants									3,149,799			3,149,799
Common stock issued upon exercise of stock options								$ 206	75,669			75,875
Common stock issued upon exercise of stock options (in Shares)								20,600
Common stock issued to consultants								$ 124	84,574			84,698
Common stock issued to consultants (in Shares)								12,400
Common stock issued upon conversion of convertible debentures			$ 14,000	$ 1,008	$ 5,214,633	$ 5,229,641		$ 3,307	2,732,042			2,735,349
Common stock issued upon conversion of convertible debentures (in Shares)			140	100,800				330,683
Common stock issued in lieu of interest on convertible debentures								$ 105	61,673			61,778
Common stock issued in lieu of interest on convertible debentures (in Shares)								10,537
Sale of common stock, net of expense								$ 6,400	3,666,735			3,673,135
Sale of common stock, net of expense (in Shares)								640,000
Acquisition of common stock in exchange for investment in Videocon Industries Limited global depository receipts									(4,134,516)			(4,134,516)
Retire common stock repurchased	$ (8,000)	$ 8,000
Retire common stock repurchased (in Shares)	(800,000)
Warrants issued in connection with issuance of convertible debentures									513,112			513,112
Common stock issued upon exercise of warrants								$ 536	299,473			300,009
Common stock issued upon exercise of warrants (in Shares)								53,598
Common stock issued to acquire patent license								$ 480	247,120			247,600
Common stock issued to acquire patent license (in Shares)								48,000
Satisfaction of loan receivable from former affiliate										$ 5,000,000		5,000,000
Net Loss											(9,606,314)	(9,606,314)
BALANCE at Oct. 31, 2014							$ 14,000	$ 87,882	148,677,413		(144,769,722)	4,009,573
BALANCE (in Shares) at Oct. 31, 2014							140	8,788,176
Stock option compensation to employees and consultants									2,676,309			2,676,309
Common stock issued upon exercise of stock options								$ 173	44,462			44,635
Common stock issued upon exercise of stock options (in Shares)								17,334
Common stock issued to consultants								$ 116	45,984			46,100
Common stock issued to consultants (in Shares)								11,600
Repurchase 92,232 shares of common stock and cancellation of warrants to purchase 16,000 shares of common stock									(343,973)			(343,973)
Acquisition of common stock in exchange for investment in Videocon Industries Limited global depository receipts												445,000
Retire common stock repurchased								$ (922)	922
Retire common stock repurchased (in Shares)								(92,232)
Net Loss											(1,379,043)	(1,379,043)
BALANCE at Oct. 31, 2015							$ 14,000	$ 87,249	$ 151,101,117		$ (146,148,765)	$ 5,053,601
BALANCE (in Shares) at Oct. 31, 2015							140	8,724,878

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (Parentheticals) - shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Treasury Stock, Shares, Acquired	92,232
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Reconciliation of net loss to net cash provided by (used in) operating activities:
Net loss	$ (1,379,043)	$ (9,606,314)
Stock option compensation to employees and consultants	2,676,309	3,149,799
Common stock issued to consultants	46,100	84,698
Amortization of patents	325,291	314,453
Accretion of interest on patent acquisition obligations to interest expense	451,906	385,770
Loss on acquisition of common stock and warrants to purchase common stock	$ 101,280
Change in value of derivative liability		592,945
Loss on extinguishment of debt		2,699,022
Accrued interest reversed on conversion of convertible debenture		173,833
Amortization of convertible debenture discount charge to interest expense		634,267
Impairment in value of investment in Videocon Industries Limited GDR’s		62,825
Common stock issued to pay interest on convertible debentures		61,778
Common stock issued to acquire patent license		16,400
Other	$ 23,195	38,225
Change in operating assets and liabilities:
Accounts receivable	400,000	(225,000)
Prepaid expenses and other current assets	(65,951)	100,069
Accounts payable and accrued expenses	(868,661)	(27,044)
Royalties and contingent legal fees payable	(347,059)	352,333
Deferred revenue		(1,187,320)
Net cash provided by (used in) operating activities	1,363,367	(2,379,261)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(2,900,000)	(5,200,000)
Proceeds from maturities of short-term investments in certificates of deposit	3,000,000	2,700,000
Purchase of property and equipment	(54,776)	(6,684)
Net cash provided by (used in) investing activities	45,224	(2,506,684)
Cash flows from financing activities:
Proceeds from issuance of convertible debentures		3,500,000
Proceeds from sale of common stock, net of expense		3,673,135
Proceeds from exercise of warrants to purchase common stock		300,009
Proceeds from exercise of employee stock options	44,635	75,875
Payments to acquire 92,232 shares of common stock and cancellation of warrants to purchase 16,000 shares of common stock	(445,253)
Payments to redeem convertible securities		(200,000)
Net cash (used in) provided by financing activities	(400,618)	7,349,019
Net increase in cash and cash equivalents	1,007,973	2,463,074
Cash and cash equivalents at beginning of year	3,361,246	898,172
Cash and cash equivalents at end of year	$ 4,369,219	3,361,246
Supplemental disclosure of non-cash investing and financing activities:
Non-cash patent acquisition		3,036,011
Common stock issued to acquire patent license		185,600
Common stock issued upon conversion of debentures		2,735,349
Fair value of debenture embedded conversion feature, at issuance		1,570,000
Relative fair value of convertible debenture warrant, at issuance		513,112
Non-cash acquisition of 20,000,000 shares of common stock		4,134,516
Common stock and preferred stock issued upon conversion of convertible debentures due November 2016		5,229,641
Cancellation of loan receivable from former affiliate		(5,000,000)
Cancellation of loan payable to former affiliate		$ 5,000,000

CONSOLIDATED STATEMENTS OF CAS9

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) - shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Number of Common Stock Acquired	92,232
Number Of Warrants Cancelled	16,000
Non-cash acquisition of common shares		20,000,000

BUSINESS AND FUNDING

BUSINESS AND FUNDING	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	BUSINESS AND FUNDING Description of Business As used herein, “ ” “ ” “ ” “ ” “ ” ’ ’ ’ ’ In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation, to develop non-invasive blood tests for the early detection of solid tumor based cancers. In July of 2015, Anixa entered into a collaborative research agreement with The Wistar Institute, the nation ’ ’ Over the next several quarters, we expect Anixa to be the primary focus of the Company. As part of our legacy operations, the Company has outsourced a small development project in connection with one of the Company ’ ’ Over the past several quarters, our revenue has been derived from technology licensing and the sale of patented technologies, including in connection with the settlement of litigation. In addition to Anixa, the Company expects to make investments in and form new companies to develop additional emerging technologies. AUO Lawsuit and Settlement On December 29, 2014, the Company and AUO Optronics Corporation ( “ ” “ ” “ ” “ ” ’ “ ” Background In May 2011, the Company entered into an Exclusive License Agreement (the “ ” “ ” “ ” “ ” On January 28, 2013, the Company terminated the AUO License Agreements due to numerous alleged material and continual breaches of the agreements by AUO. On January 28, 2013, the Company also filed a lawsuit in the United States District Court for the Northern District of California against AUO and E Ink Corporation in connection with the AUO License Agreements, alleging breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, unjust enrichment, unfair business practices, and other charges (the “ ” “ ” The Agreements Pursuant to the Settlement Agreement, AUO paid the Company $2,000,000 in U.S. currency, net of any Taiwanese withholding taxes. The Settlement Agreement further provides that: ● the Company will dismiss the AUO/E Ink Lawsuit and AUO/E Ink Arbitration, with prejudice; ● the AUO License Agreements are terminated; ● AUO gives up all rights to the nFED Technology; ● for a period of two years, the Company agrees not to initiate (whether on its own or through a third party) any patent infringement lawsuits against AUO or its affiliates alleging infringement by AUO ’ ’ ● each of AUO and the Company mutually released each other from all claims that either may have against the other in connection with the AUO License Agreements, including any claims relating to the ePaper® Electrophoretic Display and nFED patents and technologies. Pursuant to the Patent Assignment Agreement, AUO paid the Company $7,000,000 in U.S. currency, net of any Taiwanese withholding taxes in exchange for the Company ’ ● 10 active U.S. patents and 1 U.S. pending patent application; and ● 103 expired and/or abandoned U.S. and foreign patents and/or patent applications. In connection with the lawsuit and settlement, the Company incurred a total of approximately $3,604,000 of legal fees and litigation costs. Unwinding of Business Relationship and Interests with Videocon On August 29, 2014, the Company and CopyTele International Ltd., a wholly-owned subsidiary of the Company (the “ ” “ ” “ ” “ ” “ ” “ ” “ ” “ ” “ ” “ ” ’ “ ” “ ” Because Videocon was unable to continue with its joint development responsibilities, the Technology was not jointly developed by the Parties. Accordingly, the Company and Videocon agreed to terminate the Business Relationship. In order to terminate the Business Relationship, the Parties entered into several agreements whereby: (i) the License was terminated, (ii) both of the Loans were canceled and (iii) the Shares and GDRs were exchanged for each other (collectively, the “ ” Funding In November 2013, the Company completed a private placement with a single institutional investor, pursuant to which the Company issued a $3,500,000 principal amount 6% convertible debenture due November 11, 2016. On September 9, 2014, the Company and the holder of the Convertible Debenture agreed to a transaction resulting in the conversion of the principal and accrued interest of the Convertible Debenture into 739,958 shares of the Company ’ “ ” In July 2014, the Company completed the sale of 640,000 shares of its common stock at the offering price of $6.25 per share. The net proceeds from this sale totaled approximately $3,673,000. See Note 6, “ ’ – ” In October 2015, the “ “ ” “ ” “ ” ’ During the year ended October 31, 2015, cash provided by operating activities was approximately $1,363,000. Cash provided by investing activities was approximately $45,000, which resulted from the proceeds on maturity of certificates of deposit totaling $3,000,000 which was offset by the purchase of certificates of deposit totaling $2,900,000 and the purchase of property and equipment of approximately $55,000. Our cash used in financing activities was approximately $401,000, which resulted from approximately $445,000 for the repurchase of 92,232 shares of our common stock and the cancellation of warrants to purchase 16,000 shares of our common stock, offset by the proceeds from exercise of stock options of approximately $45,000. As a result, our cash, cash equivalents, and short-term investments at October 31, 2015 increased approximately $908,000 to approximately $6,769,000 from approximately $5,861,000 at the end of fiscal year 2014. Based on currently available information as of December 21, 2015, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to enable us to continue our business activities for at least 12 months. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short term investments and cash that may be generated from our business operations are insufficient to satisfy our liquidity requirements, we may seek to sell equity securities or obtain loans from various financial institutions where possible. The sale of additional equity securities or convertible debt could result in dilution to our stockholders. Additionally, the sale of equity securities or issuance of debt securities may be subject to certain security holder approvals or may result in the downward adjustment of the exercise or conversion price of our outstanding securities. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we cannot obtain such funding if needed or if we cannot sufficiently reduce operating expenses, we would need to curtail or cease some or all of our operations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of ITUS Corporation and its wholly owned subsidiaries. All intercompany transactions have been eliminated. Revenue Recognition Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed pursuant to the terms of the arrangement, (iii) amounts are fixed or determinable, and (iv) the collectability of amounts is reasonably assured. Patent Licensing In certain instances, our past revenue arrangements have provided for the payment of contractually determined fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we had no further obligations. As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met. Display Technology Development and License Fees We assessed the revenue guidance of Accounting Standards Codification ( “ ” “ ” “ ” As a result of the AUO/E Ink Lawsuit described above we did not record any display technology development and license fee revenue during the period from the fourth quarter of fiscal 2012 through the second quarter of fiscal year 2014 due to uncertainty as to our remaining performance obligations, if any. Based on our assessment performed for the third quarter of fiscal 2014, we determined that we have no further performance obligations under the AUO License Agreements and accordingly we recognized display technology development and license fee revenue of approximately $1,187,000, representing the balance of the initial $3 million payment received from AUO. On December 29, 2014, we settled our lawsuit against AUO and received gross proceeds of $9 million which was recognized as revenue in the first quarter of fiscal 2015 (see Note 1 “ – “ Inventor Royalties and Contingent Legal Fees Inventor royalties and contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Anixa Development Expenses Anixa development expenses are expensed in the consolidated statements of operations in the period incurred. Fair Value Measurements ASC 820 “ ” “ ” Financial assets and liabilities recorded in the accompanying consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial instruments whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – ’ The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2015: Level 1 Level 2 Level 3 Total Money market funds – and cash equivalents $ 467,967 $ - $ - $ 467,967 Certificates of deposit - Short term investments - 2,400,000 - 2,400,000 Total financial assets $ 467,967 $ 2,400,000 $ - $ 2,867,967 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2014: Level 1 Level 2 Level 3 Total Money market funds – and cash equivalents $ 155,964 $ - $ - $ 155,964 Certificates of deposit - Short term investments - 2,500,000 - 2,500,000 Total financial assets $ 155,964 $ 2,500,000 $ - $ 2,655,964 The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest, as of October 31, 2015: Level 1 Level 2 Level 3 Total Patent acquisition obligation - - $ 3,688,187 $ 3,688,187 The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest, as of October 31, 2014: Level 1 Level 2 Level 3 Total Patent acquisition obligation - - $ 3,236,281 $ 3,236,281 The following table sets forth a summary of the changes in the fair value of the Company ’ For the two Patent acquisition obligation: Balance October 31, 2013 $ - Initial fair value 2,850,511 Accretion of interest on patent obligation 385,770 Balance October 31, 2014 3,236,281 Accretion of interest on patent obligation 451,906 Balance October 31, 2015 $ 3,688,187 Our non-financial assets that are measured on a non-recurring basis include our property and equipment which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses, accounts payable and accrued expenses approximates their individual carrying amounts due to the short term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value. Cash and Cash Equivalents Cash equivalents consists of highly liquid, short term investments with original maturities of three months or less when purchased. Short-term Investments At October 31, 2015 and 2014, we had certificates of deposit with maturities greater than 90 days when acquired of $2,400,000 and $2,500,000, respectively, that were classified as short-term investments and reported at fair value. Patents Our only identifiable intangible assets are patents and patent rights. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life. Patent acquisition costs capitalized during the years ended October 31, 2015 and 2014, was approximately $-0- and $3,036,000, respectively. We recorded patent amortization expense of approximately $325,000 and $314,000 during the years ended October 31, 2015 and 2014, respectively. Investment Securities We classify our investment securities as available-for-sale. Available-for-sale securities are recorded at fair value. Unrealized gains and losses, net of the related tax effect, on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss) until realized. Realized gains and losses from the sale of available-for-sale securities are determined on a specific identification basis. Dividend and interest income are recognized when earned. We monitor the value of our investments for indicators of impairment, including changes in market conditions and the operating results of the underlying investment that may result in the inability to recover the carrying value of the investment. Convertible Instruments The Company accounts for hybrid contracts that feature conversion options in accordance with applicable generally accepted accounting principles ( “ ” “ ” “ ” Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. The Company accounts for convertible instruments, when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20 “ ” “ ” The conversion features of the convertible debentures issued in January 2013 and November 2013 qualified as embedded derivative instruments and were bifurcated from the host convertible debentures. Derivative liabilities are initially recorded at fair value and are then re-valued at each reporting date, with changes in fair value recognized in earnings during the reporting period. Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides a choice of net-cash settlement or settlement in the Company ’ ’ Income Taxes We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Stock-Based Compensation We maintain stock equity incentive plans under which we may grant non-qualified stock options, incentive stock options, stock appreciation rights, stock awards, performance and performance-based awards, or stock units to employees, non-employee directors and consultants. Stock Option Compensation Expense We account for stock options granted to employees and directors using the accounting guidance in ASC 718 “ ” “ ” ’ Included in stock-based compensation cost for employees and directors during the years ended October 31, 2015 and 2014 was approximately $2,092,781 and $1,426,000, respectively, related to the amortization of compensation cost for stock options granted in prior periods but not yet vested. As of October 31, 2015, there was unrecognized compensation cost related to non-vested stock options granted to employees and directors, related to service based options of approximately $432,000 which will be recognized over a weighted-average period of 1.1 years. We account for stock options granted to consultants using the accounting guidance included in ASC 505-50 “ ” “ ” ’ We recorded consulting expense, related to stock options granted to consultants, during the years ended October 31, 2015 and 2014 of approximately $484,000 and $1,022,000, respectively. Stock-based consulting expense for the years ended October 31, 2015 and 2014 includes approximately $484,000 and $964,000, respectively, related to the amortization of compensation cost for stock options granted in prior periods but vested in the current period. As of October 31, 2015, there was no unrecognized consulting expense related to non-vested stock options granted to consultants. Fair Value Determination We use the Black-Scholes pricing model in estimating the fair value of stock options which vest over a specific period of time or upon achieving performance targets. To determine the weighted average fair value of stock options on the date of grant, employees and directors are included in a single group. The fair value of stock options granted to consultants is determined on an individual basis. The stock options we granted during the year ended October 31, 2015 consisted of awards with 10-year terms that vest over one year, options with 10-year terms that vest over 36 months. The stock options we granted during the year ended October 31, 2014 consisted of awards with 10-year terms that vest over one year, options with 10-year terms that vest over 36 months, options with 5-year terms which vest immediately and options with 10-year terms which vest upon achievement of performance milestones. The following weighted average assumptions were used in estimating the fair value of stock options granted during the years ended October 31, 2015 and 2014: For the Year 2015 2014 Weighted average fair value at grant date $3.09 $5.75 Valuation assumptions: Expected life ( years) 5.75 5.80 Expected volatility 117.8% 115.3% Risk-free interest rate 2.01% 1.82% Expected dividend yield 0 0 The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. We use the simplified method to determine expected term. The simplified method was adopted since we do not believe that historical experience is representative of future performance because of the impact of the changes in our operations and the change in terms from historical options which vested immediately to terms including vesting periods of up to three years. Under the Black-Scholes pricing model, we estimated the expected volatility of our shares of common stock based upon the historical volatility of our share price over a period of time equal to the expected term of the options. We estimated the risk-free interest rate based on the implied yield available on the applicable grant date of a U.S. Treasury note with a term equal to the expected term of the underlying grants. We made the dividend yield assumption based on our history of not paying dividends and our expectation not to pay dividends in the future. Under ASC 718, the amount of stock-based compensation expense recognized is based on the portion of the awards that are ultimately expected to vest. Accordingly, if deemed necessary, we reduce the fair value of the stock option awards for expected forfeitures, which are forfeitures of the unvested portion of surrendered options. Based on our historical experience and future expectations, we have not reduced the amount of stock-based compensation expenses for anticipated forfeitures. We will reconsider use of the Black-Scholes pricing model if additional information becomes available in the future that indicates another model would be more appropriate. If factors change and we employ different assumptions in the application of ASC 718 in future periods, the compensation expense that we record under ASC 718 may differ significantly from what we have recorded in the current period. Net Loss Per Share of Common Stock In accordance with ASC 260, “ ” “ ” “ ” Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are used for, but not limited to, determining stock-based compensation, asset impairment evaluations, tax assets and liabilities, license fee revenue, the allowance for doubtful accounts, depreciation lives and other contingencies. Actual results could differ from those estimates. Effect of Recently Issued Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-09 ( “ ” In June 2014, the FASB issued Accounting Standards Update 2014-12 ( “ ” – In August 2014, the FASB issued Accounting Standards Update 2014-15 ( “ ” ’ In April 2015, the FASB issued Accounting Standards Update 2015-03 ( “ ” In November 2015, the FASB issued Accounting Standards Update 2015-17 ( “ ” Concentration of Credit Risks Financial instruments that potentially subject us to concentrations of credit risk are cash equivalents, short-term investments and accounts receivable. Cash equivalents are primarily highly rated money market funds. Short-term investments are certificates of deposit within federally insured limits. Where applicable, management reviews our accounts receivable and other receivables for potential doubtful accounts and maintains an allowance for estimated uncollectible amounts. Our policy is to write-off uncollectable amounts at the time it is determined that collection will not occur. Three licensees accounted for 53%, 37% and 10%, respectively, of revenues from patent licensing activities during fiscal year 2015. Four licensees accounted for 22%, 16%, 14% and 10%, respectively, of revenues from patent licensing activities during fiscal year 2014.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Oct. 31, 2015
Investments Schedule [Abstract]
Investment [Text Block]	INVESTMENTS Short-term Investments At October 31, 2015 and October 31, 2014, we had of certificates of deposit totaling $2,400,000 and $2,500,000, respectively. Terms of the certificates of deposit generally range from greater than three months to nine months. Investment in Videocon Our investment in Videocon was classified as an "available-for-sale security" and reported at fair value, with unrealized gains and losses excluded from operations and reported as component of accumulated other comprehensive income (loss) in shareholders ’ ’ ASC 320 “ ” “ ” “ – – ” The fair value of the Videocon GDRs on August 29, 2014, the date of disposition, was follows: Investment in Fair Value as of October 31, 2013 $ 4,197,341 Other than temporary impairment (62,825) Fair value of Videocon GDRs on date of disposition 4,134,516

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Oct. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued liabilities consist of the following as of: October 31, 2015 2014 Accounts payable $ 374,703 $ 540,179 Payroll and related expenses - 372,753 Accrued litigation expense, consulting and other professional fees - 320,493 Accrued other 6,062 16,001 Total $ 380,765 $ 1,249,426

CONVERTIBLE DEBENTURES

CONVERTIBLE DEBENTURES	12 Months Ended
	Oct. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	CONVERTIBLE DEBENTURES Convertible Debenture due January 2015 In January 2013, the Company received aggregate gross proceeds of $1,765,000 from the issuance of 8% convertible debentures due January 25, 2015 ( “ ” ’ “ ” ’ The Company determined, based upon authoritative guidance, that the conversion feature embedded within the Convertible Debenture due January 2015 should be valued separately and bifurcated from the host instrument and accounted for as a free-standing derivative liability and that the Convertible Debenture Warrant should also be valued and accounted for separately as an equity instrument. The Company determined the fair value of each of the three elements included within the Convertible Debenture due January 2015. The debenture portion (without the conversion feature) bearing interest at 8% was determined to be a debt instrument with a fair value of $1,490,000. The embedded conversion feature was determined to be a derivative liability with a fair value of $1,180,000. The Convertible Debenture Warrant was determined to be an equity instrument with a fair value of $370,000. The Company determined the fair value of each of these instruments based upon the assumptions and methodologies as discussed below. Since the Convertible Debenture Warrant was determined to be an equity instrument, the Company first computed the relative fair value of the Convertible Debenture due January 2015 (including the value of its conversion feature) with a fair value of $2,670,000 and the Convertible Debenture Warrant with a fair value of $370,000. Accordingly, the relative fair value of the Convertible Debenture Warrant and the Convertible Debenture due January 2015 (including the value of its conversion feature) was determined to be $214,819 and $1,550,181, respectively. Then, from the relative fair value of the Convertible Debenture due January 2015, the Company deducted in full the fair value of the embedded conversion feature of $1,180,000. The discount of $1,394,819 applied to the face value of the Convertible Debenture due January 2015 consists of the sum of the relative fair value of the Convertible Debenture Warrant of $214,819 and the full value of the bifurcated conversion option derivative liability of $1,180,000. The Convertible Debenture due January 2015 was recorded at a net value of $370,181, representing its face value of $1,765,000, less aggregate discounts for the derivative liability and warrant of $1,394,819, as summarized in the table below. Face value of Convertible Debenture due January 2015 $ 1,765,000 Fair value of embedded conversion feature $ 1,180,000 Relative fair value of Convertible Debenture Warrant 214,819 Discount $ 1,394,819 (1,394,819) Proceeds attributable to the Convertible Debenture due January 2015 $ 370,181 Accordingly, the Company accounted for the full amount of the discount as an offset to the Convertible Debenture due January 2015, amortizable under the effective interest method over the term of the debenture. The Company calculated the fair value of the embedded conversion feature of the Convertible Debenture due January 2015 using a Monte Carlo simulation, with the observable assumptions as provided in the table below. The significant unobservable inputs used in the fair value measurement of the reporting entity ’ As of January 25, 2013 Stock price on valuation date $ 5.25 Conversion price $ 3.75 Stock premium for liquidity 57% Term (years) 2.00 Expected volatility 110% Weighted average risk-free interest rate 0.3% Trials 100,000 Aggregate fair value $ 1,180,000 The Company calculated the fair value of the Convertible Debenture Warrant issued on January 25, 2013 using the Black-Scholes option pricing model with the following assumptions: As of January 25, 2013 Stock price on valuation date $ 5.25 Exercise price $ 7.50 Stock premium for liquidity 38% Term (years) 3.00 Warrant exercise trigger price 41% Expected volatility 95% Weighted average risk-free interest rate 0.4% Number of warrants 5,882,745 Aggregate fair value $ 370,000 The Company determined the fair value of the Convertible Debenture due January 2015 by preparing an analysis of discounted cash flows, using a discount rate of 18.6%, which the Company deemed appropriate given the Company ’ In connection with the Convertible Debenture due January 2015, the Company provided compensation to the placement agent consisting of a cash fee of $41,400 and a warrant for the purchase of 11,041 shares of the Company ’ “ ” The sum of the issuance costs was $83,760, and this cost was allocated as provided below: Attributable to: Accounting Treatment Amount The embedded conversion feature (derivative) Expensed as incurred $ 55,999 The 8% Convertible Debenture Warrant Charged to additional paid-in capital 10,194 The 8% Convertible Debenture Recorded as deferred issuance costs and amortized under the interest method over the term of the 8% Convertible Debenture 17,567 Total $ 83,760 In connection with the issuance of the Convertible Debenture due January 2015, on April 24, 2013, the Company prepared and filed a registration statement registering for resale the shares of its common stock which may be issued upon the conversion of the debenture consistent with the terms and conditions of the registration rights agreement the Company entered into with the holders of the registrable shares listed above. The registration statement was declared effective by the SEC on June 19, 2013. The Company has agreed to maintain the effectiveness of the registration statement through the earlier of three years from the date of the issuance of the Convertible Debenture due January 2015 or until Rule 144 of the Securities Act is available to the holders to allow them to sell all of their registrable securities thereunder. The derivative liability related to the embedded conversion feature was revalued at each reporting period as well as on the date of all conversions, as discussed, below. As of October 31, 2013, the Company determined the fair value of the derivative liability to be $540,000, and accordingly, during the year ended October 31, 2013, the Company recorded a gain on the change in the fair value of the derivative liability of approximately $475,000. As of October 31, 2014, the Company determined the fair value of the derivative liability to be $-0-, as the full value of the Convertible Debenture due January 2015 was converted and/or repaid in full during the year ended October 31, 2014 and accordingly, during the year ended October 31, 2014, the Company recorded a loss on the change in the fair value of the derivative of approximately $1,131,000. As of October 31, 2013, the Company calculated the fair value of the embedded conversion feature of the Convertible Debenture due January 2015 using a Monte Carlo simulation, with the observable assumptions as provided in the table below. The significant unobservable inputs used in the fair value measurement of the reporting entity ’ As of October 31, 2013 Stock price on valuation date $ 4.875 Conversion price $ 3.75 Stock premium for liquidity 42% Term (years) 1.25 Expected volatility 115% Weighted average risk-free interest rate 0.3% Trials 100,000 Aggregate fair value $ 540,000 The fair value of the derivative liability associated with the conversions and repayments of the Convertible Debenture due January 2015 was approximately $1,671,000 immediately prior to the conversions and repayments. As of April 30, 2014, the Convertible Debenture due January 2015 was extinguished in full. However, the Company needed to determine the fair value of the derivative liability for the embedded conversion feature immediately prior to the conversion, in order to determine the change in the fair value of the derivative for the period. The Company determined to measure the derivative immediately prior to the conversion at its intrinsic value, since this method most fairly measured the value of the derivative liability. The intrinsic value computation is provided below. As of April 30, 2014 Stock price used for valuation $ 8.50 266.68 shares issued per $1,000 face value Aggregate intrinsic value of the $1,150,000 of principal outstanding on April 30, 2014, immediately prior to conversion and repayment $ 1,456,797 The amortization of debt discount related to the Convertible Debenture due January 2015 was approximately $-0- and $233,000, for the years ended October 31, 2015 and 2014, respectively. During the year ended October 31, 2013, holders of $325,000 and $5,878 of principal and interest, respectively, of the Convertible Debenture due January 2015, converted their holdings into an aggregate of 86,671 and 805 shares of Common Stock. During the year ended October 31, 2014, holders of $1,240,000 and $9,000 of principal and interest, respectively, of the Convertible Debenture due January 2015, converted their holdings into an aggregate of 330,683 and 1,185 shares of common stock and holders of $200,000 of principal of the Convertible Debenture due January 2015 consented to prepayment (without conversion) of obligations to them under the instrument ’ The loss on extinguishment of debt was calculated as follows: Year Ended October 31, 2014 Face value of debt converted $ 1,440,000 Less: discount (658,232) Plus: fair value of derivative liability 1,670,704 Net book value of debt converted $ 2,452,472 Fair value of common stock issued 2,935,387 Loss on extinguishment of debt $ (482,915) Convertible Debenture due November 2016 In November 2013, the Company received aggregate gross proceeds of $3,500,000 from the issuance of 6% convertible debentures due November 11, 2016 ( “ ” “ ” ’ The Company determined, based upon authoritative guidance, that the conversion feature embedded within the Convertible Debenture due November 2016 should be valued separately and bifurcated from the host instrument and accounted for as a free-standing derivative liability and that the Convertible Debenture Warrant should also be valued and accounted for separately as an equity instrument. The Company determined the fair value of each of the three elements included within the Convertible Debenture due November 2016. The debenture portion (without the conversion feature) bearing interest at 6% was determined to be a debt instrument with a fair value of $2,710,000. The embedded conversion feature was determined to be a derivative liability with a fair value of $1,570,000. The Convertible Debenture Warrant was determined to be an equity instrument with a fair value of $740,000. The Company determined the fair value of each of these instruments based upon the assumptions and methodologies as discussed below. Since the Convertible Debenture Warrant was determined to be an equity instrument, the Company first computed the relative fair value of the Convertible Debenture due November 2016 (including the value of its conversion feature) with a fair value of $4,280,000 and the Convertible Debenture Warrant with a fair value of $740,000. Accordingly, the relative fair value of the Convertible Debenture Warrant and the Convertible Debenture due November 2016 (including the value of its conversion feature) was determined to be $515,936 and $2,984,064, respectively. Then, from the relative fair value of the Convertible Debenture due November 2016, the Company deducted in full the fair value of the embedded conversion feature of $1,570,000. The discount of $2,085,936 applied to the face value of the Convertible Debenture due November 2016 consists of the sum of the relative fair value of the Convertible Debenture Warrant of $515,936 and the full value of the bifurcated conversion option derivative liability of $1,570,000. The Convertible Debenture due November 2016 was recorded at a net value of $1,414,064, representing its face value of $3,500,000, less aggregate discounts for the derivative liability and warrant of $2,085,936, as summarized in the table below. Face value of Convertible Debenture due November 2016 $ 3,500,000 Fair value of embedded conversion feature $ 1,570,000 Relative fair value of Convertible Debenture Warrant 515,936 Discount $ 2,085,936 (2,085,936) Proceeds attributable to the Convertible Debenture due November 2016 $ 1,414,064 Accordingly, the Company accounted for the full amount of the discount as an offset to the Convertible Debenture due November 2016, amortizable under the effective interest method over the term of the debenture. The Company calculated the fair value of the embedded conversion feature of the Convertible Debenture due November 2016 using a Monte Carlo simulation, with the observable assumptions as provided in the table below. The significant unobservable inputs used in the fair value measurement of the reporting entity ’ As of November 11, 2013 Stock price on valuation date $ 5.00 Conversion price $ 4.725 Discount for lack of marketability 35.5% Term (years) 3.00 Expected volatility 102.8% Weighted average risk-free interest rate 0.62% Trials 100,000 Aggregate fair value $ 1,570,000 The Company calculated the fair value of the Convertible Debenture Warrant issued on November 11, 2013 using a Black Scholes Model, with the observable assumptions as provided in the table below. The significant unobservable inputs used in the fair value measurement of the reporting entity ’ As of November 11, 2013 Stock price on valuation date $ 5.00 Exercise price $ 9.45 Discount for lack of marketability 22% Term (years) 3.00 Expected volatility 102.8% Weighted average risk-free interest rate 0.6% Number of warrants 369,979 Aggregate fair value $ 740,000 The Company determined the fair value of the Convertible Debenture due November 2016 by preparing an analysis of discounted cash flows, using a discount rate of 16.0%, which the Company deemed appropriate given the Company ’ In connection with the issuance of the Convertible Debenture due November 2016, the Company incurred legal costs which were allocated as provided below: Attributable to: Accounting Treatment Amount The embedded conversion feature (derivative) Expensed as incurred $ 8,593 The 8% Convertible Debenture Warrant Charged to additional paid-in capital 2,824 The 8% Convertible Debenture Recorded as deferred issuance costs and amortized under the interest method over the term of the 8% Convertible Debenture 7,739 Total $ 19,156 In connection with the issuance of the Convertible Debenture due November 2016, on February 7, 2014, the Company prepared and filed a registration statement registering for resale the shares of its common stock which may be issued upon the conversion of the debenture and exercise of the warrant consistent with the terms and conditions of the debenture agreement the Company entered into with the holders of the registrable shares listed above. The Company has agreed to maintain the effectiveness of the registration statement through the earlier of three years from the date of the issuance of the Convertible Debenture due November 2016 or until Rule 144 of the Securities Act is available to the holders to allow them to sell all of their registrable securities thereunder. On September 9, 2014, holders of $3,500,000 and approximately $173,000 of principal and interest, respectively, of the Convertible Debenture due November 2016, converted their holdings into an aggregate of 739,958 shares of common stock the ( “ ” Immediately after the conversion, the holders exchanged 639,158 shares of the Conversion Common Stock into 3,500 shares of Series A Convertible Preferred Stock. Shortly thereafter, the Company retired and cancelled the 639,158 shares of common stock received in the exchange. In connection with this conversion, the Company recorded a loss on conversion/exchange of approximately $2,216,000, as summarized below. This loss represents the excess of the fair value of the common stock issued, net of the shares of common stock exchanged for the issuance of 3,500 shares of Series A Convertible Preferred Stock, plus the fair value of the Series A Convertible Preferred Stock, on the date of the conversion, over the net book value of the debt on the date of conversion. Since the conversion feature on the Convertible Debenture due November 2016 was determined to be a derivative liability, the net book value includes the value of the debt, net of debt discount and deferred issuance costs, plus accrued interest and the derivative liability related to the conversion feature (after being marked to market) on the conversion date, and the change in the fair value of the warrant on the date of the conversion. Because the conversion rate of the Series A Convertible Preferred Stock of $ 4.73 per share was less than the Company ’ beneficial conversion feature. The beneficial conversion feature was recorded in additional paid-in-capital as a result of the Company ’ . The loss on extinguishment of debt was determined as follows: Securities extinguished: Face value of convertible debenture converted $ 3,500,000 Less: debt discount (1,684,801) Less: deferred issuance costs (7,739) Plus: accrued interest 173,833 Plus: fair value of derivative liability 1,032,241 Plus: fair value of warrant exchanged in connection with the conversion 805,000 Net book value of converted debenture, accrued interest, derivative liability and warrant exchanged 3,818,534 Securities issued in conversion/exchange: Fair value of 100,800 shares of common stock issued, net (739,958 shares of Conversion Common Stock issued, less 639,158 shares exchanged for 3,500 shares of Series A Convertible Preferred Stock) 617,400 Fair value of 3,500 shares of Series A Convertible Preferred Stock (based on a stated value per share of $1,000 and a conversion rate of $4.73) 4,532,241 Fair value of warrant issued September 9, 2014 885,000 Subtotal of securities issued in conversion/exchange 6,034,641 (Loss) on conversion/exchange $ (2,216,107) On September 9, 2014, the Convertible Debenture due November 2016 was extinguished in full. The Company needed to determine the fair value of the derivative liability for the embedded conversion feature immediately prior to the conversion, in order to determine the change in the fair value of the derivative for the period. The Company determined to measure the derivative immediately prior to the conversion at its intrinsic value, since this method most fairly measured the value of the derivative liability. The intrinsic value computation is provided below. On September 9, 2014 Stock price used for valuation $ 6.125 211.4 shares issued per $1,000 of face value Aggregate gross intrinsic value of the $3,500,000 of principal outstanding on September 8, 2014, immediately prior to conversion 4,532,241 Less the face value of the convertible debenture (3,500,000) Intrinsic value of the derivative conversion feature $ 1,032,241 The derivative liability related to the embedded conversion feature was revalued at each reporting period as well as on the date of all conversions. The value of the derivative liability associated with the conversion of the Convertible Debenture due November 2016 during the year ended October 31, 2014 was approximately $1,032,000. As of October 31, 2014, the Company determined the fair value of the derivative liability to be $-0-, as the full value of the Convertible Debenture due November 2016 was converted in full during the year ended October 31, 2014. During the year ended October 31, 2014, the Company recorded gains on the change in fair value of the derivative liability of approximately $538,000. The Company calculated the fair value of the embedded conversion feature of the Convertible Debenture due November 2016 using a Monte Carlo simulation. The significant unobservable inputs used in the fair value measurement of the reporting entity ’ The amortization of debt discount related to the Convertible Debenture due November 2016 for the years ended October 31, 2015 and 2014 was approximately $-0- and $401,000, respectively.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Oct. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	SHAREHOLDERS ’ Sale of Common Stock On July 15, 2014, the Company, raised $4,000,000 of gross proceeds via a registered direct offering of its common stock to certain investors (the “ ” “ ” 640, 000 shares of common stock and warrants to purchase an aggregate of 320, 000 shares of common stock. The purchase price of one share of common stock and a warrant to purchase ½ of a share of common stock was $ 6 .25. The warrants are exercisable immediately as of the date of issuance at an exercise price of $ 10.00 per share and expire five years from the date of issuance. The exercise price of the warrants is subject to customary adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. Under certain circumstances, the Company has the right to call for cancellation of warrants for which a notice of exercise has not yet been delivered for consideration equal to $.0 25 per share. The Offering was effected as a takedown off the Company ’ Reverse Stock Split On June 26, 2015, we effected a 1-for-25 reverse stock split (the “ ” ’ Common Stock Issuances During the years ended October 31, 2015 and 2014, we issued 11,600 shares and 12,400 shares, respectively, of common stock to consultants for services rendered, pursuant to the 2010 Share Plan. We recorded consulting expense for the years ended October 31, 2015 and 2014 of approximately $46,000 and $85,000, respectively, for shares of common stock issued to consultants. Stock Option Plans As of October 31, 2015, we have two stock option plans: the 2003 Share Plan and the 2010 Share Plan which were adopted by our Board of Directors on April 21, 2003 and July 14, 2010, respectively. The 2003 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to key employees and consultants. The maximum number of shares of common stock in the 2003 Share Plan was 2,800,000 shares. The 2003 Share Plan was administered by the Stock Option Committee through June 2004, from June 2004 through July 2010, by the Board of Directors, from July 2010 through August 2012, by the Stock Option Committee, from August 2012 through November 2012, by the Executive Committee of the Board of Directors and since November 2012, by the Board of Directors, which determined the option price, term and provisions of each option. The exercise price with respect to all of the options granted under the 2003 Share Plan since its inception was equal to the fair market value of the underlying common stock at the grant date. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the grant of future options on April 21, 2013. Information regarding the 2003 Share Plan for the two years ended October 31, 2015 is as follows: Shares Weighted Aggregate Options Outstanding at October 31, 2013 625,554 $ 18.00 Exercised (17,400) $ 3.63 Forfeited (114,163) $ 19.75 Options Outstanding at October 31, 2014 493,991 $ 18.00 Exercised (4,000) $ 2.58 Forfeited (123,771) $ 14.71 Options Outstanding and Exercisable at October 31, 2015 366,200 $ 17.86 $ 61,665 The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of October 31, 2015: Range of Number Weighted Average Contractual Life (in years) Weighted Average $ 1.79 - $ 9.25 73,880 1.75 $ 2.91 $14.75 - $17.25 59,600 1.33 $16.75 $18.75 - $23.00 192,720 1.14 $21.57 $29.25 40,000 1.80 $29.25 The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to key employees and consultants. The maximum number of shares of common stock in the 2010 Share Plan was initially 600,000 shares. On July 6, 2011, the 2010 Share Plan was amended by our Board of Directors to increase the maximum number of shares of common stock in the plan to 1,080,000 shares and on August 29, 2012, the maximum number of shares in the plan was further increased to 1,200,000 shares. On November 8, 2013, the Board of Directors approved an amendment to provide that effective November 8, 2013, the maximum aggregate number of shares available for future issuance will be 800,000 shares and that on the first business day in 2014 and on the first business day of each calendar year thereafter the maximum aggregate number of shares available for future issuance shall be replenished such that 800,000 shares will be available. Accordingly, on November 8, 2013, January 2, 2014 and January 2, 2015, the number of shares in the 2010 Share Plan was increased to 1,956,999 shares, 2,225,399 shares and 2,569,399 shares, respectively. In addition, on November 8, 2013, the 2010 Share Plan was amended to provide that on January 2nd of each year commencing on January 2, 2014, each non-employee director of the Company at that time shall automatically be granted a 10 year stock option to purchase 12,000 shares of common stock (16,000 for the Chairman) that will vest in four equal quarterly installments. The 2010 Share Plan was administered by the Stock Option Committee through August 2012, from August 2012 through November 2012, by the Executive Committee of the Board of Directors and since November 2012, by the Board of Directors, which determines the option price, term and provisions of each option. The exercise price with respect to all of the options granted under the 2010 Share Plan was equal to the fair market value of the underlying common stock at the grant date. As of October 31, 2015, the 2010 Share Plan had 988,995 shares available for future grants. Information regarding the 2010 Share Plan as of October 31, 2015 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options Outstanding at October 31, 2013 119,360 $6.13 Granted 612,400 $5.75 Exercised (3,200) $4.00 Options Outstanding at October 31, 2014 728,560 $5.75 Granted 60,400 $2.91 Exercised (13,334) $2.58 Forfeited (249,355) $6.24 Options Outstanding at October 31, 2015 526,271 $3.33 $ 471,292 Options Exercisable at October 31, 2015 406,149 $3.40 $ 342,572 The following table summarizes information about stock options outstanding under the 2010 Share Plan as of October 31, 2015: Options Outstanding Options Exercisable Range of Number Weighted Average (in years) Weighted Average Number Weighted Average Weighted Average $2.58 - $9.25 526,271 6.98 $3.33 406,149 6.57 $3.40 . In addition to options granted under the 2003 Share Plan and the 2010 Share Plan, in September 2012, the Board of Directors approved the grant of stock options to purchase 1,660,000 shares and, during the year ended October 31, 2013, the Board of Directors approved the grant of stock options to purchase 120,000 shares. Of the stock options granted in September 2012, nonqualified options to purchase 1,600,000 shares were issued to our new executive team, consisting of 640,000 stock options issued to our new President and Chief Executive Officer, 320,000 stock options issued to our new Senior Vice President of Engineering and 640,000 stock options issued to a new strategic advisor to the Company who was also a Director. These stock options had an exercise price of $5.44 (the average of the high and the low sales price of the common stock on the trading day immediately preceding the approval of such options by the Board of Directors) and have a term of ten years. Half of these stock options vest in 36 equal monthly installments commencing on October 31, 2012, provided that if the grantees are terminated by the Company without cause, an additional 12 months of vesting will be accelerated and such accelerated options will become immediately exercisable. The balance of the stock options will vest in three equal installments upon achievement of a cash milestone, which was satisfied in the fourth quarter of fiscal 2013, and two stock price targets, which were not achieved in fiscal 2013. In November 2013, in light of the cost and expense of revaluing the unvested portion of the performance-based stock options on a quarterly basis for financial reporting purposes, the Board of Directors approved an amendment to the performance-based stock options awarded on September 19, 2012 to the President and Chief Executive Officer, Senior Vice President of Engineering and the strategic advisor. The amendment modifies the option award ’ ’ The remaining nonqualified stock options granted in September 2012 to purchase 60,000 shares consisted of grants of 30,000 stock options to our Chairman in compensation for his service as interim Chief Executive Officer of the Company and as compensation for his prior service as a director, and 30,000 stock options to a director in compensation for his service in recruiting the Company ’ , based on our closing share price on October 31, 2015 of $3.72 ’ During the year ended October 31, 2013, nonqualified stock options to purchase 120,000 shares were granted to our outside directors for service rendered to our Company. Of these options, (a) In November 2012, nonqualified stock options to purchase 40,000 shares were issued to one of our directors as additional compensation for service in recruiting the Company ’ (b) In February 2013, nonqualified stock options to purchase 40,000 shares were issued to the Chairman of the Board. These stock options had an exercise price of $5.88 (the average of the high and low sales price on date of grant) and vest 13,334 shares upon grant and 13,333 shares in two annual installments commencing February 15, 2014. (c) In March 2013, nonqualified stock options to purchase an aggregate of 40,000 shares were granted to the Company ’ As of October 31, 2015, the options to purchase 120,000 shares were exercisable and had an intrinsic value of approximately $92,000 , based on our closing share price on October 31, 2015 of $3.72 ’ The following table summarizes information about the above outstanding and exercisable stock options that were not granted under the 2003 Share Plan or the 2010 Share Plan as of October 31, 2015: Range of Number Weighted Average (in years) Weighted Average $ 2.58 - $ 5.56 1,780,000 6.76 $ 2.71 . On January 28, 2015, the Board of Directors authorized management of the Company to re-price issued and outstanding stock options for all of the officers, directors and employees of the Company, at any time prior to February 16, 2015. On February 5, 2015, management acted to re-price 2,184,125 issued and outstanding stock options (the “ ” ’ Preferred Stock In May 1986, our shareholders authorized 200,000 shares of preferred stock with a par value of $100 per share. The shares of preferred stock may be issued in series at the direction of the Board of Directors, and the relative rights, preferences and limitations of such shares will all be determined by the Board of Directors. Series A Convertible Preferred Stock On September 9, 2014, the Company designated 140 shares of the preferred stock as Series A Convertible Preferred Stock, par value $100 per share, in accordance with the Certificate of Designation of Series A Convertible Preferred Stock filed with the Secretary of State of the State of Delaware on September 9, 2014 (the “ ” “ ” Ranking The Series A Convertible Preferred Stock ranks senior to the Company ’ Optional Conversion Holders of the Series A Convertible Preferred Stock may at any time convert their shares of Series A Convertible Preferred Stock into such number of shares of the Company ’ “ ” “ ” The holder shall not have the right to convert any portion of the Series A Convertible Preferred Stock if after giving effect to such conversion, the holder, together with any affiliate thereof, would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. The embedded conversion option has certain anti-dilution protection provisions which would be triggered if the Company issues its common stock, or certain common stock equivalents, (as defined) at a price below $3.55 per share. Mandatory Conversion At any time after November 11, 2016, if and only if the average of the high and low trading prices of the Company ’ “ ” “ ” Redemption At any time on or after November 11, 2016 (the “ ” “ ” “ ” ’ “ ” ’ Board and Observer Rights Each holder of Series A Convertible Preferred Stock shall have the right, upon 10 days' prior written notice, to designate one representative, reasonably acceptable to the Company, who shall be entitled to attend and observe meetings of the Company ’ “ ” Accounting for the Series A Convertible Preferred Stock The Company determined that the economic characteristics and risks of the conversion feature and the preferred stock instrument were clearly and closely related as equity instruments and accordingly, the conversion feature would not require separate accounting. In addition, the redemption feature is contingent upon Series A Convertible Preferred Stock not being converted into common stock and upon the holders delivering a redemption notice to the Company. Further, the redemption purchase price may only be paid from the proceeds of a subsequent sale of equity securities. Accordingly, the Series A Convertible Preferred Stock was accounted for as an equity instrument. Further, b ecause the conversion rate of the Series A Convertible Preferred Stock of $ 4.73 per share was less than the Company ’ beneficial conversion feature. The beneficial conversion feature was recorded in additional paid-in-capital as a result of the Company ’ .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Oct. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	COMMITMENTS AND CONTINGENCIES Patent Acquisition Obligations As of October 31, 2015, we have incurred obligations due no later than November 2017 related to the acquisition of patents, which have a discounted present value of approximately $3,688,000, and which amount will be reduced by royalties paid during the period, if any. The payment due in November 2017 is payable at the option of the Company in cash or common stock. We recorded interest expense of approximately $452,000 and $386,000, respectively, for the years ended October 31, 2015 and 2014, for the accretion of interest on patent acquisition obligations. Leases We lease approximately 3,000 square feet of office space in Los Angeles, California pursuant to a lease that expires March 30, 2016. As of October 31, 2015, our non-cancelable operating lease commitments for the year ending October 31, 2016 was approximately $44,000. Rent expense for the years ended October 31, 2015 and 2014, was approximately $100,000 and $109,000, respectively. Litigation Matters On December 29, 2014, we settled our lawsuit against AUO which had been filed on January 28, 2013. For a more detailed description of the settlement with AUO see Note 1, “ ” Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business. We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	INCOME TAXES Income tax provision (benefit) consists of the following: Year Ended October 31, 2015 2014 Federal: Current $ - $ - Deferred (487,000) (1,606,000) State: Current - - Deferred (120,000) (1,000) Adjustment to valuation allowance related to net deferred tax assets 607,000 1,607,000 Income tax provision (benefit) $ - $ - The tax effects of temporary differences that give rise to significant portions of the deferred tax asset, net, at October 31, 2015 and 2014, are as follows: 2015 2014 Long-term deferred tax assets: Federal and state NOL and tax credit carryforwards $ 31,261,000 $ 31,864,000 Deferred compensation 6,522,000 5,437,000 Intangibles 483,000 - Other 282,000 359,000 Subtotal 38,548,000 37,660,000 Less: valuation allowance (38,548,000) (37,660,000) Deferred tax asset, net $ - $ - As of October 31, 2015, we had tax net operating loss and tax credit carryforwards of approximately $75,642,000 and $1,110,000, respectively, available within statutory limits (expiring at various dates between 2016 and 2035), to offset any future regular Federal corporate taxable income and taxes payable. If the tax benefits relating to deductions of option holders ’ We had New York State tax net operating loss and tax credit carryforwards of approximately $72,505,000 and $11,000, respectively, and California tax net operating loss carryforward of approximately $2,803,000, as of October 31, 2015, available within statutory limits (expiring at various dates between 2016 and 2035), to offset future corporate taxable income and taxes payable, if any, under certain computations of such taxes. We have provided a valuation allowance against our deferred tax asset due to our current and historical pre-tax losses and the uncertainty regarding their realizability. The primary differences from the Federal statutory rate of 34% and the effective rate of 0% is attributable to certain permanent differences and a change in the valuation allowance. The following is a reconciliation of income taxes at the Federal statutory tax rate to income tax expense (benefit): Year Ended October 31, 2015 2014 Income tax benefit at U.S. Federal statutory income Tax rate $ (469,000) (34.00%) $ (3,266,000) (34.00%) State income taxes (117,000) (8.50%) (6,000) (.06%) Permanent differences 1,000 .10% 1,529,000 15.92% Expiring net operating losses, credits and other (22,000) (1.60%) 115,000 1.19% Foreign rate difference on impairment - 0% 21,000 .22% Change in valuation allowance 607,000 44.00% 1,607,000 16.73% Income tax provision $ - 0% $ - 0% During the two fiscal years ended October 31, 2015, we incurred no Federal and no State income taxes. We have no unrecognized tax benefits as of October 31, 2015 and 2014 and we account for interest and penalties related to income tax matters in marketing, general and administrative expenses. Tax years to which our net operating losses relate remain open to examination by Federal authorities and other jurisdictions to the extent which the net operating losses have yet to be utilized.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Oct. 31, 2015
Accounting Policies, by Policy (Policies) [Line Items]
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation The consolidated financial statements include the accounts of ITUS Corporation and its wholly owned subsidiaries. All intercompany transactions have been eliminated.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed pursuant to the terms of the arrangement, (iii) amounts are fixed or determinable, and (iv) the collectability of amounts is reasonably assured. Patent Licensing In certain instances, our past revenue arrangements have provided for the payment of contractually determined fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we had no further obligations. As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met. Display Technology Development and License Fees We assessed the revenue guidance of Accounting Standards Codification ( “ ” “ ” “ ” As a result of the AUO/E Ink Lawsuit described above we did not record any display technology development and license fee revenue during the period from the fourth quarter of fiscal 2012 through the second quarter of fiscal year 2014 due to uncertainty as to our remaining performance obligations, if any. Based on our assessment performed for the third quarter of fiscal 2014, we determined that we have no further performance obligations under the AUO License Agreements and accordingly we recognized display technology development and license fee revenue of approximately $1,187,000, representing the balance of the initial $3 million payment received from AUO. On December 29, 2014, we settled our lawsuit against AUO and received gross proceeds of $9 million which was recognized as revenue in the first quarter of fiscal 2015 (see Note 1 “ – “ Inventor Royalties and Contingent Legal Fees Inventor royalties and contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Anixa Development Expenses Anixa development expenses are expensed in the consolidated statements of operations in the period incurred.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements ASC 820 “ ” “ ” Financial assets and liabilities recorded in the accompanying consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial instruments whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – ’ The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2015: Level 1 Level 2 Level 3 Total Money market funds – and cash equivalents $ 467,967 $ - $ - $ 467,967 Certificates of deposit - Short term investments - 2,400,000 - 2,400,000 Total financial assets $ 467,967 $ 2,400,000 $ - $ 2,867,967 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2014: Level 1 Level 2 Level 3 Total Money market funds – and cash equivalents $ 155,964 $ - $ - $ 155,964 Certificates of deposit - Short term investments - 2,500,000 - 2,500,000 Total financial assets $ 155,964 $ 2,500,000 $ - $ 2,655,964 The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest, as of October 31, 2015: Level 1 Level 2 Level 3 Total Patent acquisition obligation - - $ 3,688,187 $ 3,688,187 The following table presents the hierarchy for our financial liabilities measured at fair value on the transaction date and then adjusted for the subsequent accretion of interest, as of October 31, 2014: Level 1 Level 2 Level 3 Total Patent acquisition obligation - - $ 3,236,281 $ 3,236,281 The following table sets forth a summary of the changes in the fair value of the Company ’ For the two Patent acquisition obligation: Balance October 31, 2013 $ - Initial fair value 2,850,511 Accretion of interest on patent obligation 385,770 Balance October 31, 2014 3,236,281 Accretion of interest on patent obligation 451,906 Balance October 31, 2015 $ 3,688,187 Our non-financial assets that are measured on a non-recurring basis include our property and equipment which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses, accounts payable and accrued expenses approximates their individual carrying amounts due to the short term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash equivalents consists of highly liquid, short term investments with original maturities of three months or less when purchased.
Investment, Policy [Policy Text Block]	Short-term Investments At October 31, 2015 and 2014, we had certificates of deposit with maturities greater than 90 days when acquired of $2,400,000 and $2,500,000, respectively, that were classified as short-term investments and reported at fair value.
Marketable Securities, Policy [Policy Text Block]	Investment Securities We classify our investment securities as available-for-sale. Available-for-sale securities are recorded at fair value. Unrealized gains and losses, net of the related tax effect, on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss) until realized. Realized gains and losses from the sale of available-for-sale securities are determined on a specific identification basis. Dividend and interest income are recognized when earned. We monitor the value of our investments for indicators of impairment, including changes in market conditions and the operating results of the underlying investment that may result in the inability to recover the carrying value of the investment.
Convertible Instruments Policy [Policy Text Block]	Convertible Instruments The Company accounts for hybrid contracts that feature conversion options in accordance with applicable generally accepted accounting principles ( “ ” “ ” “ ” Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. The Company accounts for convertible instruments, when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20 “ ” “ ” The conversion features of the convertible debentures issued in January 2013 and November 2013 qualified as embedded derivative instruments and were bifurcated from the host convertible debentures. Derivative liabilities are initially recorded at fair value and are then re-valued at each reporting date, with changes in fair value recognized in earnings during the reporting period.
Stockholders' Equity, Policy [Policy Text Block]	Common Stock Purchase Warrants The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides a choice of net-cash settlement or settlement in the Company ’ ’
Income Tax, Policy [Policy Text Block]	Income Taxes We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation We maintain stock equity incentive plans under which we may grant non-qualified stock options, incentive stock options, stock appreciation rights, stock awards, performance and performance-based awards, or stock units to employees, non-employee directors and consultants.
Compensation Related Costs, Policy [Policy Text Block]	Stock Option Compensation Expense We account for stock options granted to employees and directors using the accounting guidance in ASC 718 “ ” “ ” ’ Included in stock-based compensation cost for employees and directors during the years ended October 31, 2015 and 2014 was approximately $2,092,781 and $1,426,000, respectively, related to the amortization of compensation cost for stock options granted in prior periods but not yet vested. As of October 31, 2015, there was unrecognized compensation cost related to non-vested stock options granted to employees and directors, related to service based options of approximately $432,000 which will be recognized over a weighted-average period of 1.1 years. We account for stock options granted to consultants using the accounting guidance included in ASC 505-50 “ ” “ ” ’ We recorded consulting expense, related to stock options granted to consultants, during the years ended October 31, 2015 and 2014 of approximately $484,000 and $1,022,000, respectively. Stock-based consulting expense for the years ended October 31, 2015 and 2014 includes approximately $484,000 and $964,000, respectively, related to the amortization of compensation cost for stock options granted in prior periods but vested in the current period. As of October 31, 2015, there was no unrecognized consulting expense related to non-vested stock options granted to consultants.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Determination We use the Black-Scholes pricing model in estimating the fair value of stock options which vest over a specific period of time or upon achieving performance targets. To determine the weighted average fair value of stock options on the date of grant, employees and directors are included in a single group. The fair value of stock options granted to consultants is determined on an individual basis. The stock options we granted during the year ended October 31, 2015 consisted of awards with 10-year terms that vest over one year, options with 10-year terms that vest over 36 months. The stock options we granted during the year ended October 31, 2014 consisted of awards with 10-year terms that vest over one year, options with 10-year terms that vest over 36 months, options with 5-year terms which vest immediately and options with 10-year terms which vest upon achievement of performance milestones. The following weighted average assumptions were used in estimating the fair value of stock options granted during the years ended October 31, 2015 and 2014: For the Year 2015 2014 Weighted average fair value at grant date $3.09 $5.75 Valuation assumptions: Expected life ( years) 5.75 5.80 Expected volatility 117.8% 115.3% Risk-free interest rate 2.01% 1.82% Expected dividend yield 0 0 The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. We use the simplified method to determine expected term. The simplified method was adopted since we do not believe that historical experience is representative of future performance because of the impact of the changes in our operations and the change in terms from historical options which vested immediately to terms including vesting periods of up to three years. Under the Black-Scholes pricing model, we estimated the expected volatility of our shares of common stock based upon the historical volatility of our share price over a period of time equal to the expected term of the options. We estimated the risk-free interest rate based on the implied yield available on the applicable grant date of a U.S. Treasury note with a term equal to the expected term of the underlying grants. We made the dividend yield assumption based on our history of not paying dividends and our expectation not to pay dividends in the future. Under ASC 718, the amount of stock-based compensation expense recognized is based on the portion of the awards that are ultimately expected to vest. Accordingly, if deemed necessary, we reduce the fair value of the stock option awards for expected forfeitures, which are forfeitures of the unvested portion of surrendered options. Based on our historical experience and future expectations, we have not reduced the amount of stock-based compensation expenses for anticipated forfeitures. We will reconsider use of the Black-Scholes pricing model if additional information becomes available in the future that indicates another model would be more appropriate. If factors change and we employ different assumptions in the application of ASC 718 in future periods, the compensation expense that we record under ASC 718 may differ significantly from what we have recorded in the current period.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share of Common Stock In accordance with ASC 260, “ ” “ ” “ ”
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are used for, but not limited to, determining stock-based compensation, asset impairment evaluations, tax assets and liabilities, license fee revenue, the allowance for doubtful accounts, depreciation lives and other contingencies. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Effect of Recently Issued Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-09 ( “ ” In June 2014, the FASB issued Accounting Standards Update 2014-12 ( “ ” – In August 2014, the FASB issued Accounting Standards Update 2014-15 ( “ ” ’ In April 2015, the FASB issued Accounting Standards Update 2015-03 ( “ ” In November 2015, the FASB issued Accounting Standards Update 2015-17 ( “ ”
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risks Financial instruments that potentially subject us to concentrations of credit risk are cash equivalents, short-term investments and accounts receivable. Cash equivalents are primarily highly rated money market funds. Short-term investments are certificates of deposit within federally insured limits. Where applicable, management reviews our accounts receivable and other receivables for potential doubtful accounts and maintains an allowance for estimated uncollectible amounts. Our policy is to write-off uncollectable amounts at the time it is determined that collection will not occur. Three licensees accounted for 53%, 37% and 10%, respectively, of revenues from patent licensing activities during fiscal year 2015. Four licensees accounted for 22%, 16%, 14% and 10%, respectively, of revenues from patent licensing activities during fiscal year 2014.
Patents [Member]
Accounting Policies, by Policy (Policies) [Line Items]
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents Our only identifiable intangible assets are patents and patent rights. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life. Patent acquisition costs capitalized during the years ended October 31, 2015 and 2014, was approximately $-0- and $3,036,000, respectively. We recorded patent amortization expense of approximately $325,000 and $314,000 during the years ended October 31, 2015 and 2014, respectively.

SUMMARY OF SIGNIFICANT ACCOUN19

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Oct. 31, 2015
Accounting Policies [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Money market funds – and cash equivalents $ 467,967 $ - $ - $ 467,967 Certificates of deposit - Short term investments - 2,400,000 - 2,400,000 Total financial assets $ 467,967 $ 2,400,000 $ - $ 2,867,967 Level 1 Level 2 Level 3 Total Money market funds – and cash equivalents $ 155,964 $ - $ - $ 155,964 Certificates of deposit - Short term investments - 2,500,000 - 2,500,000 Total financial assets $ 155,964 $ 2,500,000 $ - $ 2,655,964 Level 1 Level 2 Level 3 Total Patent acquisition obligation - - $ 3,688,187 $ 3,688,187 Level 1 Level 2 Level 3 Total Patent acquisition obligation - - $ 3,236,281 $ 3,236,281
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	For the two Patent acquisition obligation: Balance October 31, 2013 $ - Initial fair value 2,850,511 Accretion of interest on patent obligation 385,770 Balance October 31, 2014 3,236,281 Accretion of interest on patent obligation 451,906 Balance October 31, 2015 $ 3,688,187
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Year 2015 2014 Weighted average fair value at grant date $3.09 $5.75 Valuation assumptions: Expected life ( years) 5.75 5.80 Expected volatility 117.8% 115.3% Risk-free interest rate 2.01% 1.82% Expected dividend yield 0 0

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Oct. 31, 2015
Investments Schedule [Abstract]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Table Text Block]	Investment in Fair Value as of October 31, 2013 $ 4,197,341 Other than temporary impairment (62,825) Fair value of Videocon GDRs on date of disposition 4,134,516

ACCOUNTS PAYABLE AND ACCRUED 21

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Oct. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	October 31, 2015 2014 Accounts payable $ 374,703 $ 540,179 Payroll and related expenses - 372,753 Accrued litigation expense, consulting and other professional fees - 320,493 Accrued other 6,062 16,001 Total $ 380,765 $ 1,249,426

CONVERTIBLE DEBENTURES (Tables)

CONVERTIBLE DEBENTURES (Tables)	12 Months Ended
	Oct. 31, 2015
Convertible Debenture Due November 2016 [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]	On September 9, 2014 Stock price used for valuation $ 6.125 211.4 shares issued per $1,000 of face value Aggregate gross intrinsic value of the $3,500,000 of principal outstanding on September 8, 2014, immediately prior to conversion 4,532,241 Less the face value of the convertible debenture (3,500,000) Intrinsic value of the derivative conversion feature $ 1,032,241
Convertible Debenture Warrant [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]	As of November 11, 2013 Stock price on valuation date $ 5.00 Exercise price $ 9.45 Discount for lack of marketability 22% Term (years) 3.00 Expected volatility 102.8% Weighted average risk-free interest rate 0.6% Number of warrants 369,979 Aggregate fair value $ 740,000
Schedule of Debt Issuance Cost [Table Text Block]	Attributable to: Accounting Treatment Amount The embedded conversion feature (derivative) Expensed as incurred $ 8,593 The 8% Convertible Debenture Warrant Charged to additional paid-in capital 2,824 The 8% Convertible Debenture Recorded as deferred issuance costs and amortized under the interest method over the term of the 8% Convertible Debenture 7,739 Total $ 19,156
Convertible Debenture Due January 2015 [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Convertible Debt [Table Text Block]	Face value of Convertible Debenture due January 2015 $ 1,765,000 Fair value of embedded conversion feature $ 1,180,000 Relative fair value of Convertible Debenture Warrant 214,819 Discount $ 1,394,819 (1,394,819) Proceeds attributable to the Convertible Debenture due January 2015 $ 370,181
Schedule of Debt Issuance Cost [Table Text Block]	Attributable to: Accounting Treatment Amount The embedded conversion feature (derivative) Expensed as incurred $ 55,999 The 8% Convertible Debenture Warrant Charged to additional paid-in capital 10,194 The 8% Convertible Debenture Recorded as deferred issuance costs and amortized under the interest method over the term of the 8% Convertible Debenture 17,567 Total $ 83,760
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]	As of April 30, 2014 Stock price used for valuation $ 8.50 266.68 shares issued per $1,000 face value Aggregate intrinsic value of the $1,150,000 of principal outstanding on April 30, 2014, immediately prior to conversion and repayment $ 1,456,797
Schedule of Extinguishment of Debt [Table Text Block]	Year Ended October 31, 2014 Face value of debt converted $ 1,440,000 Less: discount (658,232) Plus: fair value of derivative liability 1,670,704 Net book value of debt converted $ 2,452,472 Fair value of common stock issued 2,935,387 Loss on extinguishment of debt $ (482,915)
Convertible Debenture Due January 2015 [Member] | Convertible Debentures Embedded Conversion Feature [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]	As of January 25, 2013 Stock price on valuation date $ 5.25 Conversion price $ 3.75 Stock premium for liquidity 57% Term (years) 2.00 Expected volatility 110% Weighted average risk-free interest rate 0.3% Trials 100,000 Aggregate fair value $ 1,180,000 As of October 31, 2013 Stock price on valuation date $ 4.875 Conversion price $ 3.75 Stock premium for liquidity 42% Term (years) 1.25 Expected volatility 115% Weighted average risk-free interest rate 0.3% Trials 100,000 Aggregate fair value $ 540,000
Convertible Debenture Due January 2015 [Member] | Convertible Debenture Warrant [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]	As of January 25, 2013 Stock price on valuation date $ 5.25 Exercise price $ 7.50 Stock premium for liquidity 38% Term (years) 3.00 Warrant exercise trigger price 41% Expected volatility 95% Weighted average risk-free interest rate 0.4% Number of warrants 5,882,745 Aggregate fair value $ 370,000
Convertible Debenture Due November 2016 [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Convertible Debt [Table Text Block]	Face value of Convertible Debenture due November 2016 $ 3,500,000 Fair value of embedded conversion feature $ 1,570,000 Relative fair value of Convertible Debenture Warrant 515,936 Discount $ 2,085,936 (2,085,936) Proceeds attributable to the Convertible Debenture due November 2016 $ 1,414,064
Convertible Debenture Due November 2016 [Member] | Convertible Debentures Embedded Conversion Feature [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]	As of November 11, 2013 Stock price on valuation date $ 5.00 Conversion price $ 4.725 Discount for lack of marketability 35.5% Term (years) 3.00 Expected volatility 102.8% Weighted average risk-free interest rate 0.62% Trials 100,000 Aggregate fair value $ 1,570,000
Convertible Debenture Due November 2016 [Member]
CONVERTIBLE DEBENTURES (Tables) [Line Items]
Schedule of Extinguishment of Debt [Table Text Block]	Securities extinguished: Face value of convertible debenture converted $ 3,500,000 Less: debt discount (1,684,801) Less: deferred issuance costs (7,739) Plus: accrued interest 173,833 Plus: fair value of derivative liability 1,032,241 Plus: fair value of warrant exchanged in connection with the conversion 805,000 Net book value of converted debenture, accrued interest, derivative liability and warrant exchanged 3,818,534 Securities issued in conversion/exchange: Fair value of 100,800 shares of common stock issued, net (739,958 shares of Conversion Common Stock issued, less 639,158 shares exchanged for 3,500 shares of Series A Convertible Preferred Stock) 617,400 Fair value of 3,500 shares of Series A Convertible Preferred Stock (based on a stated value per share of $1,000 and a conversion rate of $4.73) 4,532,241 Fair value of warrant issued September 9, 2014 885,000 Subtotal of securities issued in conversion/exchange 6,034,641 (Loss) on conversion/exchange $ (2,216,107)

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Oct. 31, 2015
SHAREHOLDERS' EQUITY (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Shares Weighted Aggregate Options Outstanding at October 31, 2013 625,554 $ 18.00 Exercised (17,400) $ 3.63 Forfeited (114,163) $ 19.75 Options Outstanding at October 31, 2014 493,991 $ 18.00 Exercised (4,000) $ 2.58 Forfeited (123,771) $ 14.71 Options Outstanding and Exercisable at October 31, 2015 366,200 $ 17.86 $ 61,665 Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options Outstanding at October 31, 2013 119,360 $6.13 Granted 612,400 $5.75 Exercised (3,200) $4.00 Options Outstanding at October 31, 2014 728,560 $5.75 Granted 60,400 $2.91 Exercised (13,334) $2.58 Forfeited (249,355) $6.24 Options Outstanding at October 31, 2015 526,271 $3.33 $ 471,292 Options Exercisable at October 31, 2015 406,149 $3.40 $ 342,572
2003 Share Plan [Member]
SHAREHOLDERS' EQUITY (Tables) [Line Items]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Range of Number Weighted Average Contractual Life (in years) Weighted Average $ 1.79 - $ 9.25 73,880 1.75 $ 2.91 $14.75 - $17.25 59,600 1.33 $16.75 $18.75 - $23.00 192,720 1.14 $21.57 $29.25 40,000 1.80 $29.25
2010 Share Plan [Member]
SHAREHOLDERS' EQUITY (Tables) [Line Items]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Range of Number Weighted Average (in years) Weighted Average Number Weighted Average Weighted Average $2.58 - $9.25 526,271 6.98 $3.33 406,149 6.57 $3.40 .
Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]
SHAREHOLDERS' EQUITY (Tables) [Line Items]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Range of Number Weighted Average (in years) Weighted Average $ 2.58 - $ 5.56 1,780,000 6.76 $ 2.71 .

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended October 31, 2015 2014 Federal: Current $ - $ - Deferred (487,000) (1,606,000) State: Current - - Deferred (120,000) (1,000) Adjustment to valuation allowance related to net deferred tax assets 607,000 1,607,000 Income tax provision (benefit) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2015 2014 Long-term deferred tax assets: Federal and state NOL and tax credit carryforwards $ 31,261,000 $ 31,864,000 Deferred compensation 6,522,000 5,437,000 Intangibles 483,000 - Other 282,000 359,000 Subtotal 38,548,000 37,660,000 Less: valuation allowance (38,548,000) (37,660,000) Deferred tax asset, net $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended October 31, 2015 2014 Income tax benefit at U.S. Federal statutory income Tax rate $ (469,000) (34.00%) $ (3,266,000) (34.00%) State income taxes (117,000) (8.50%) (6,000) (.06%) Permanent differences 1,000 .10% 1,529,000 15.92% Expiring net operating losses, credits and other (22,000) (1.60%) 115,000 1.19% Foreign rate difference on impairment - 0% 21,000 .22% Change in valuation allowance 607,000 44.00% 1,607,000 16.73% Income tax provision $ - 0% $ - 0%

BUSINESS AND FUNDING (Details)

BUSINESS AND FUNDING (Details) - USD ($)	Dec. 29, 2014	Sep. 09, 2014	Aug. 29, 2014	Jul. 15, 2014	Jul. 31, 2014	Nov. 30, 2013	Oct. 31, 2015	Oct. 31, 2014
BUSINESS AND FUNDING (Details) [Line Items]
Proceeds from Legal Settlements							$ 2,000,000
Legal Fees							3,604,000
Sale of Stock, Number of Shares Issued in Transaction (in Shares)					640,000
Sale of Stock, Price Per Share (in Dollars per share)					$ 6.25
Proceeds from Issuance of Common Stock				$ 4,000,000	$ 3,673,000			$ 3,673,135
Common Stock, Value, Issued							87,249	87,882
Net Cash Provided by (Used in) Operating Activities							1,363,367	(2,379,261)
Net Cash Provided by (Used in) Investing Activities							45,224	(2,506,684)
Proceeds from Maturities, Prepayments and Calls of Short-term Investments							3,000,000
Payments to Acquire Short-term Investments							2,900,000	5,200,000
Payments to Acquire Property, Plant, and Equipment							54,776	6,684
Net Cash Provided by (Used in) Financing Activities							(400,618)	7,349,019
Stock Repurchased During Period, Value							$ 445,000	$ (4,134,516)
Stock Repurchased During Period, Shares (in Shares)							92,232
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)							16,000
Proceeds from Stock Options Exercised							$ 44,635	$ 75,875
Cash, Period Increase (Decrease)							908,000
Cash, Cash Equivalents, and Short-term Investments							6,769,000	$ 5,861,000
Convertible Debenture [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Proceeds from Issuance of Private Placement						$ 3,500,000
Debt Instrument, Interest Rate, Stated Percentage						6.00%
Common Stock [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)		739,958
Conversion of Stock, Shares Converted (in Shares)		639,159
Convertible Preferred Stock [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)		3,500
National Securities Corporation [Member] | Agreement [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Common Stock, Value, Issued							10,000,000
AUO Settlement [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Proceeds from Legal Settlements	$ 9,000,000
Patent Assignment Agreement [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Proceeds from Legal Settlements							$ 7,000,000
Subsidiary Loan [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Debt of Subsidiary, Not Assumed			$ 5,000,000
Mars Loan [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Debt of Subsidiary, Not Assumed			$ 5,000,000
Sale of Stock, Number of Shares Issued in Transaction (in Shares)			800,000
Global Depository Receipts [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)			1,495,845

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 29, 2014	Oct. 31, 2015	Oct. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
License and Services Revenue			$ 1,187,320
Proceeds from Legal Settlements		$ 2,000,000
Short-term Investments		$ 2,400,000	$ 2,500,000
Convertible Preferred Stock [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)		739,958
Awards Of Options With 10 Year Terms [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Award Vesting Period, Description		The stock options we granted during the year ended October 31, 2015 consisted of awards with 10-year terms that vest over one year, options with 10-year terms that vest over 36 months.	The stock options we granted during the year ended October 31, 2014 consisted of awards with 10-year terms that vest over one year, options with 10-year terms that vest over 36 months, options with 5-year terms which vest immediately and options with 10-year terms which vest upon achievement of performance milestones.
Employee Stock Option [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)		2,672,471	3,002,550
AUO License Agreement [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
License and Services Revenue		$ 3,000,000
License Agreement, Aggregate License Fee		10,000,000
License Agreement, Contingent License Fee, Receivable		7,000,000
Deferred Revenue, Current			$ 1,187,000
AUO Settlement [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Proceeds from Legal Settlements	$ 9,000,000
Stock Award Granted To Employees And Consultants [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		0
Share-based Compensation		484,000	1,022,000
Amortization Related To Compensation Cost		484,000	964,000
Stock Options Granted To Employees And Directors [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		432,000
Share-based Compensation		2,192,000	2,128,000
Amortization Related To Compensation Cost		$ 2,092,781	$ 1,426,000
Property, Plant and Equipment, Useful Life		1 year 36 days
Warrant [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)		1,028,931	1,044,931
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Licensees 1 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		53.00%	22.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Licensees 2 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		37.00%	16.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Licensees 3 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		10.00%	14.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Licensees 4 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			10.00%
Patents [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Acquisition Costs, Period Cost		$ 0	$ 3,036,000
Amortization of Acquisition Costs		$ 325,000	$ 314,000

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis - USD ($)	Oct. 31, 2015	Oct. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Patent acquisition obligation	$ 3,688,187	$ 3,236,281
Global Depository Receipts [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments		2,500,000
Total financial assets		2,655,964
Money Market Funds [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Money market funds – Cash and cash equivalents	467,967	$ 155,964
Certificates of Deposit [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments	2,400,000
Total financial assets	$ 2,867,967
Fair Value, Inputs, Level 1 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Patent acquisition obligation
Fair Value, Inputs, Level 1 [Member] | Global Depository Receipts [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments
Total financial assets		$ 155,964
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Money market funds – Cash and cash equivalents	$ 467,967	$ 155,964
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments
Total financial assets	$ 467,967
Fair Value, Inputs, Level 2 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Patent acquisition obligation
Fair Value, Inputs, Level 2 [Member] | Global Depository Receipts [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments		$ 2,500,000
Total financial assets		$ 2,500,000
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Money market funds – Cash and cash equivalents
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments	$ 2,400,000
Total financial assets	2,400,000
Fair Value, Inputs, Level 3 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Patent acquisition obligation	$ 3,688,187	$ 3,236,281
Fair Value, Inputs, Level 3 [Member] | Global Depository Receipts [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments
Total financial assets
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Money market funds – Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Hierarchy for our financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Investments
Total financial assets

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Summary of the changes in the fair value of the Company's Level 3 financial liabilities on recurring basis (Incomplete) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Patent acquisition obligation:
Initial fair value	$ 3,688,187	$ 3,236,281
Accretion of interest on patent obligation	451,906	$ 385,770
Balance	3,688,187
Patent Acquisition Obligation [Member]
Patent acquisition obligation:
Balance October 31, 2013	3,236,281
Initial fair value		$ 2,850,511
Accretion of interest on patent obligation	$ 451,906	385,770
Balance		$ 3,236,281

SUMMARY OF SIGNIFICANT ACCOUN29

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Weighted average assumptions used in estimating the fair value of stock options - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Weighted average assumptions used in estimating the fair value of stock options [Abstract]
Weighted average fair value at grant date (in Dollars per share)	$ 3.09	$ 5.75
Valuation assumptions:
Expected life ( years)	5 years 9 months	5 years 292 days
Expected volatility	117.80%	115.30%
Risk-free interest rate	2.01%	1.82%
Expected dividend yield	0.00%	0.00%

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($)	10 Months Ended
	Aug. 29, 2014	Oct. 31, 2015	Oct. 31, 2014	Nov. 30, 2007
INVESTMENTS (Details) [Line Items]
Certificates of Deposit, at Carrying Value		$ 2,400,000	$ 2,500,000
Investment In Videocon [Member]
INVESTMENTS (Details) [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis				$ 16,200,000
Equity Method Investment, Other than Temporary Impairment	$ 63,000
Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset	$ 4,135,000
Shares Exchanged for GDR (in Shares)	800,000
Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held	$ 12,065,000

INVESTMENTS (Details) - The fai

INVESTMENTS (Details) - The fair value of investment - Investment In Videocon [Member]	10 Months Ended
	Aug. 29, 2014USD ($)
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Fair Value as of October 31, 2013	$ 4,197,341
Fair value of Videocon GDRs on date of disposition	4,134,516
Other than temporary impairment	$ (62,825)

ACCOUNTS PAYABLE AND ACCRUED 32

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued liabilities - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Accounts payable and accrued liabilities [Abstract]
Accounts payable	$ 374,703	$ 540,179
Payroll and related expenses		372,753
Accrued litigation expense, consulting and other professional fees		320,493
Accrued other	$ 6,062	16,001
Total	$ 380,765	$ 1,249,426

CONVERTIBLE DEBENTURES (Details

CONVERTIBLE DEBENTURES (Details)	Sep. 30, 2014USD ($)$ / sharesshares	Nov. 30, 2013USD ($)$ / sharesshares	Jan. 31, 2013USD ($)$ / shares	Oct. 31, 2015USD ($)$ / sharesshares	Oct. 31, 2014USD ($)shares	Oct. 31, 2013USD ($)shares	Jan. 25, 2015$ / shares	Dec. 31, 2014USD ($)
CONVERTIBLE DEBENTURES (Details) [Line Items]
Proceeds from Convertible Debt					$ 3,500,000
Debt Instrument Prepayment Threshold Trading Days Ending Prior To Prepayment Notice				15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares				16,000
Convertible Debt				$ 1,414,064
Legal Fees				3,604,000
Debt Issuance Cost				$ 19,156	$ 83,760
Derivative, Gain (Loss) on Derivative, Net					(592,945)
Amortization of Debt Discount (Premium)					634,267
Gains (Losses) on Extinguishment of Debt					(2,699,022)
Convertible Debenture Due January 2015 [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Proceeds from Convertible Debt			$ 1,765,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%	8.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares							$ 3.75
Debt Instrument, Convertible, Stock Price Trigger (in Dollars per share) | $ / shares			$ 3.75	$ 7.50
Debt Instrument, Convertible, Threshold Trading Days			10
Debt Instrument Prepayment Notice Period			30 days
Debt Instrument Prepayment Threshold Trading Days				20
Debt Instrument Prepayment Threshold Trading Days Ending Prior To Prepayment Notice				30
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares				11,041
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares) | shares				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 7.50
Convertible Debt, Fair Value Disclosures				$ 1,490,000
Plus: fair value of derivative liability				1,180,000				$ 1,671,000
Warrants Not Settleable in Cash, Fair Value Disclosure				370,000
Relative fair value of Convertible Debenture Warrant				214,819
Convertible Debt Instrument Including Embedded Derivative Relative Fair Value				1,550,181
Debt Instrument, Unamortized Discount				(1,394,819)
Convertible Debt				370,181
Debt Instrument, Face Amount				1,765,000	200,000	$ 325,000
Derivative Liability and Warrant				$ 1,394,819
Fair Value Inputs, Discount Rate				18.60%
Cash Fee Compensation Placement Agent				$ 41,400
Legal Fees				25,000
Debt Issuance Cost				83,760
Derivative Liability, Current					0	540,000
Derivative, Gain (Loss) on Derivative, Net					1,131,000	475,000
Amortization of Debt Discount (Premium)				0	233,000
Debt Instrument, Increase, Accrued Interest					$ 9,000	$ 5,878
Debt Instrument Convertible Number Of Equity Instruments For Principal (in Shares) (in Shares) | shares					330,683	86,671
Debt Instrument Convertible Number Of Equity Instruments For Interest (in Shares) (in Shares) | shares					1,185	805
Gains (Losses) on Extinguishment of Debt					$ 482,915
Convertible Debenture Due January 2015 [Member] | Placement Agent Warrant [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Relative fair value of Convertible Debenture Warrant				17,360
Convertible Debenture Due January 2015 [Member] | Management [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Proceeds from Convertible Debt			$ 250,000
Convertible Debenture Due January 2015 [Member] | Convertible Debentures Embedded Conversion Feature [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Plus: fair value of derivative liability				1,180,000
Warrants Not Settleable in Cash, Fair Value Disclosure				370,000
Relative fair value of Convertible Debenture Warrant				$ 214,819
Debt Instrument, Face Amount					1,240,000
Convertible Debenture Due November 2016 [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Proceeds from Convertible Debt		$ 3,500,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%		6.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 7.75	$ 9.46
Debt Instrument Prepayment Notice Period		30 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares	369,979	369,979
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares) | shares		1
Convertible Debt, Fair Value Disclosures						$ 4,280,000
Plus: fair value of derivative liability						1,570,000
Warrants Not Settleable in Cash, Fair Value Disclosure						740,000
Relative fair value of Convertible Debenture Warrant						515,936
Convertible Debt Instrument Including Embedded Derivative Relative Fair Value						2,984,064
Debt Instrument, Unamortized Discount				$ (2,085,936)
Convertible Debt	$ 3,500,000			$ 1,414,064
Fair Value Inputs, Discount Rate				16.00%
Derivative Liability, Current					1,032,000
Derivative, Gain (Loss) on Derivative, Net					538,000
Amortization of Debt Discount (Premium)				$ 0	401,000
Debt Instrument, Increase, Accrued Interest	$ 173,000
Debt Conversion Converted Instrument Additional Shares Issued (in Shares) (in Shares) | shares		3.55
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares	739,958
Conversion of Stock, Shares Converted (in Shares) | shares	639,158
Conversion of Stock, Shares Issued (in Shares) | shares	3,500
Retirement and Cancellation Of Shares (in Shares) (in Shares) | shares	639,158
(Loss) on conversion/exchange	$ 2,216,000
Equity Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 4.73
Derivative, Fair Value, Net					$ 0
Convertible Debenture Due November 2016 [Member] | Convertible Debentures Embedded Conversion Feature [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 4.73
Debt Instrument, Unamortized Discount				(2,085,936)
Convertible Debenture Without Conversion Features [Member] | Convertible Debenture Due January 2015 [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Convertible Debt, Fair Value Disclosures				$ 2,670,000
Convertible Debenture Without Conversion Features [Member] | Convertible Debenture Due November 2016 [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Convertible Debt, Fair Value Disclosures						2,710,000
Plus: fair value of derivative liability						1,570,000
Relative fair value of Convertible Debenture Warrant						$ 740,000
Convertible Debenture Warrant [Member] | Convertible Debenture Due January 2015 [Member]
CONVERTIBLE DEBENTURES (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares				235,310
Relative fair value of Convertible Debenture Warrant				$ 214,819

CONVERTIBLE DEBENTURES (Detai34

CONVERTIBLE DEBENTURES (Details) - Convertible Debenture - USD ($)	Oct. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Oct. 31, 2013
CONVERTIBLE DEBENTURES (Details) - Convertible Debenture [Line Items]
Proceeds attributable to the Convertible Debenture due January 2015	$ 370,181
Convertible Debenture Due January 2015 [Member]
CONVERTIBLE DEBENTURES (Details) - Convertible Debenture [Line Items]
Face value of Convertible Debenture due January 2015	1,765,000		$ 200,000	$ 325,000
Fair value of embedded conversion feature	1,180,000	$ 1,671,000
Relative fair value of Convertible Debenture Warrant	214,819
Discount	$ (1,394,819)

CONVERTIBLE DEBENTURES (Detai35

CONVERTIBLE DEBENTURES (Details) - Fair value of the embedded conversion feature of the Convertible Debenture - Convertible Debentures Embedded Conversion Feature [Member] - USD ($)	Jan. 25, 2013	Oct. 31, 2014
Assumption for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Line Items]
Stock price on valuation date (in Dollars per share)	$ 5.25	$ 4.875
Conversion price (in Dollars per share)	$ 3.75	$ 3.75
Stock premium for liquidity	57.00%	42.00%
Term (years)	2 years	1 year 3 months
Expected volatility	110.00%	115.00%
Weighted average risk-free interest rate	0.30%	0.30%
Trials (in Shares)	100,000	100,000
Aggregate fair value (in Dollars)	$ 1,180,000	$ 540,000

CONVERTIBLE DEBENTURES (Detai36

CONVERTIBLE DEBENTURES (Details) - Fair value of the Convertible - Convertible Debenture Warrant [Member]	Jan. 25, 2013USD ($)$ / sharesshares
Assumption for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Line Items]
Stock price on valuation date (in Dollars per share)	$ 5.25
Exercise price (in Dollars per share)	$ 7.50
Stock premium for liquidity	38.00%
Term (years)	3 years
Warrant exercise trigger price	41.00%
Expected volatility	95.00%
Weighted average risk-free interest rate	0.40%
Number of warrants (in Shares) | shares	5,882,745
Aggregate fair value (in Dollars) | $	$ 370,000

CONVERTIBLE DEBENTURES (Detai37

CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	$ 19,156	$ 83,760
Expensed As Incurred [Member]
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	8,593	55,999
Charged To Additional Paid In Capital [Member]
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	2,824	10,194
Recorded As Deferred Issuance Costs And Amortized Under The Interest Method Over The Term Of The 8 Convertible Debenture [Member]
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	$ 7,739	$ 17,567

CONVERTIBLE DEBENTURES (Detai38

CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation - Convertible Debenture [Member]	Apr. 30, 2014USD ($)$ / shares
CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation [Line Items]
Stock price used for valuation | $ / shares	$ 8.50
	266.68 shares issued per $1,000 face value
Aggregate intrinsic value of the $1,150,000 of principal outstanding on April 30, 2014, immediately prior to conversion and repayment | $	$ 1,456,797

CONVERTIBLE DEBENTURES (Detai39

CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation (Parentheticals) - Convertible Debenture [Member]	Apr. 30, 2014USD ($)shares
CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation (Parentheticals) [Line Items]
Issuance of shares | shares	266.68
Aggregate intrinsic value | $	$ 1,150,000

CONVERTIBLE DEBENTURES (Detai40

CONVERTIBLE DEBENTURES (Details) - The loss on extinguishment of debt - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Extinguishment of Debt [Line Items]
Fair value of common stock issued		$ 5,229,641
Loss on extinguishment of debt		(2,699,022)
Convertible Debenture Due January 2015 [Member]
Extinguishment of Debt [Line Items]
Face value of debt converted		1,440,000
Less: discount		(658,232)
Plus: fair value of derivative liability		1,670,704
Net book value of debt converted		2,452,472
Fair value of common stock issued		2,935,387
Loss on extinguishment of debt		$ (482,915)

CONVERTIBLE DEBENTURES (Detai41

CONVERTIBLE DEBENTURES (Details) - Convertible Debenture	Oct. 31, 2015USD ($)
CONVERTIBLE DEBENTURES (Details) - Convertible Debenture [Line Items]
Proceeds attributable to the Convertible Debenture due November 2016	$ 1,414,064
Convertible Debenture Due November 2016 [Member]
CONVERTIBLE DEBENTURES (Details) - Convertible Debenture [Line Items]
Face value of Convertible Debenture due November 2016	3,500,000
Fair value of embedded conversion feature	1,570,000
Relative fair value of Convertible Debenture Warrant	515,936
Discount	$ 2,085,936

CONVERTIBLE DEBENTURES (Detai42

CONVERTIBLE DEBENTURES (Details) - Fair value of the embedded conversion feature of the Convertible Debenture - USD ($)	Nov. 11, 2013	Jan. 25, 2013	Oct. 31, 2014	Oct. 31, 2015
Convertible Debentures Embedded Conversion Feature [Member]
Assumption for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Line Items]
Stock price on valuation date (in Dollars per share)		$ 5.25	$ 4.875
Conversion price (in Dollars per share)		$ 3.75	$ 3.75
Term (years)		2 years	1 year 3 months
Expected volatility		110.00%	115.00%
Weighted average risk-free interest rate		0.30%	0.30%
Trials (in Shares)		100,000	100,000
Aggregate fair value (in Dollars)		$ 1,180,000	$ 540,000
Convertible Debenture Due November 2016 [Member]
Assumption for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Line Items]
Aggregate fair value (in Dollars)				$ 1,570,000
Convertible Debenture Due November 2016 [Member] | Convertible Debentures Embedded Conversion Feature [Member]
Assumption for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Line Items]
Stock price on valuation date (in Dollars per share)	$ 5
Conversion price (in Dollars per share)	$ 4.725
Discount for lack of marketability	35.50%
Term (years)	3 years
Expected volatility	102.80%
Weighted average risk-free interest rate	0.62%
Trials (in Shares)	100,000
Aggregate fair value (in Dollars)	$ 1,570,000

CONVERTIBLE DEBENTURES (Detai43

CONVERTIBLE DEBENTURES (Details) - Fair value of the Convertible Debenture Warrant - 8% Convertible Debenture Warrant [Member]	Nov. 11, 2013USD ($)$ / sharesshares
Assumption for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Line Items]
Stock price on valuation date (in Dollars per share)	$ 5
Exercise price (in Dollars per share)	$ 9.45
Discount for lack of marketability	22.00%
Term (years)	3 years
Expected volatility	102.80%
Weighted average risk-free interest rate	0.60%
Number of warrants (in Shares) | shares	369,979
Aggregate fair value (in Dollars) | $	$ 740,000

CONVERTIBLE DEBENTURES (Detai44

CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	$ 19,156	$ 83,760
Expensed As Incurred [Member]
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	8,593	55,999
Charged To Additional Paid In Capital [Member]
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	2,824	10,194
Recorded As Deferred Issuance Costs And Amortized Under The Interest Method Over The Term Of The 8 Convertible Debenture [Member]
CONVERTIBLE DEBENTURES (Details) - Issuance Cost Allocation [Line Items]
Allocated issuance costs	$ 7,739	$ 17,567

CONVERTIBLE DEBENTURES (Detai45

CONVERTIBLE DEBENTURES (Details) - The loss on extinguishment of debt - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Securities extinguished:
Less: deferred issuance costs	$ 19,156	$ 83,760
Convertible Debenture Due November 2016 [Member]
Securities extinguished:
Face value of convertible debenture converted	3,500,000
Plus: fair value of derivative liability	1,570,000
Net book value of converted debenture, accrued interest, derivative liability and warrant exchanged	3,818,534
Securities issued in conversion/exchange:
Subtotal of securities issued in conversion/exchange	6,034,641
(Loss) on conversion/exchange	(2,216,107)
Convertible Debenture Due November 2016 [Member] | Convertible Debenture [Member]
Securities issued in conversion/exchange:
Fair value of 100,800 shares of common stock issued, net (739,958 shares of Conversion Common Stock issued, less 639,158 shares exchanged for 3,500 shares of Series A Convertible Preferred Stock)	617,400
Fair value of 3,500 shares of Series A Convertible Preferred Stock (based on a stated value per share of $1,000 and a conversion rate of $4.73)	4,532,241
Fair value of warrant issued September 9, 2014	885,000
Long-term Debt [Member] | Convertible Debenture Due November 2016 [Member]
Securities extinguished:
Face value of convertible debenture converted	3,500,000
Less: debt discount	(1,684,801)
Less: deferred issuance costs	(7,739)
Plus: accrued interest	173,833
Plus: fair value of derivative liability	1,032,241
Plus: fair value of warrant exchanged in connection with the conversion	$ 805,000

CONVERTIBLE DEBENTURES (Detai46

CONVERTIBLE DEBENTURES (Details) - The loss on extinguishment of debt (Parentheticals) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Extinguishment of Debt [Line Items]
Common stock issued, net	8,724,878	8,788,176
Series A Preferred Stock [Member]
Extinguishment of Debt [Line Items]
Preferred Stock	140	140
Convertible Debenture Due November 2016 [Member]
Extinguishment of Debt [Line Items]
Common stock issued, net	100,800
Common Stock issued on Conversion	739,958
Less: Shares exchnaged for Series A Convertible Preferred Stock	639,158
Convertible Debenture Due November 2016 [Member] | Series A Preferred Stock [Member]
Extinguishment of Debt [Line Items]
Preferred Stock	3,500
Preferred Stock, Stated value (in Dollars per share)	$ 1,000
Preferred Stock, Conversion Price (in Dollars per share)	$ 4.73

CONVERTIBLE DEBENTURES (Detai47

CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation - 8% Convertible Debenture [Member]	Sep. 09, 2013USD ($)$ / shares
CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation [Line Items]
Stock price used for valuation (in Dollars per share) | $ / shares	$ 6.125
	211.4 shares issued per $1,000 of face value
Aggregate gross intrinsic value of the $3,500,000 of principal outstanding on September 8, 2014, immediately prior to conversion	$ 4,532,241
Less the face value of the convertible debenture	(3,500,000)
Intrinsic value of the derivative conversion feature	$ 1,032,241

CONVERTIBLE DEBENTURES (Detai48

CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation (Parentheticals) - 8% Convertible Debenture [Member]	Sep. 09, 2013USD ($)shares
CONVERTIBLE DEBENTURES (Details) - Intrinsic Value Computation (Parentheticals) [Line Items]
Issuance of shares | shares	211.4
Aggregate intrinsic value | $	$ 3,500,000

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - USD ($)

Feb. 15, 2015

Feb. 05, 2015

Jan. 02, 2015

Nov. 30, 2014

Sep. 09, 2014

Jul. 15, 2014

Feb. 15, 2014

Jan. 02, 2014

Nov. 30, 2013

Nov. 08, 2013

Sep. 30, 2012

Jul. 31, 2014

Mar. 31, 2013

Feb. 28, 2013

Nov. 30, 2012

Oct. 31, 2015

Oct. 31, 2014

Oct. 31, 2013

Nov. 30, 2015

Aug. 29, 2012

Jul. 06, 2011

Jul. 14, 2010

Apr. 21, 2003

May. 31, 1986

SHAREHOLDERS' EQUITY (Details) [Line Items]

Proceeds from Issuance of Common Stock (in Dollars)

$ 4,000,000

$ 3,673,000

$ 3,673,135

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

16,000

Series A Preferred Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$ 100

$ 100

2010 Share Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

600,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

988,995

Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)

2,569,399

2,225,399

1,956,999

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

60,400

612,400

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 2.91

$ 5.75

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

406,149

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

$ 342,572

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)

$ 3.40

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

526,271

728,560

119,360

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)

$ 3.33

$ 5.75

$ 6.13

2010 Share Plan [Member] | Employee Stock Option [Member] | Consultant [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Stock Issued During Period, Shares, Issued for Services

11,600

12,400

Consultation Fees Related To Options (in Dollars) (in Dollars)

$ 46,000

$ 85,000

2003 Share Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

2,800,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

493,991

625,554

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)

$ 18

$ 18

2010 Share Plan Amendmend [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,200,000

1,080,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

800,000

2010 Share Plan Amendmend [Member] | Employee Stock Option [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

2010 Share Plan Amendmend [Member] | Employee Stock Option [Member] | Non Employee Director [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

12,000

2010 Share Plan Amendmend [Member] | Employee Stock Option [Member] | Board of Directors Chairman [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

16,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,660,000

120,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,600,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 5.44

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

1,600,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

$ 1,832,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)

$ 3.72

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | Directors Additional Compensation Service [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

40,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 5.28

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

13,333

13,334

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | Board of Directors Chairman [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

40,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

13,333

13,334

Common Stock, Anti-dilution Threshold Price (in Dollars per share) (in Dollars per share)

$ 5.88

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | President and Chief Executive Officer [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

640,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | Senior Vice President of Engineering [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

320,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | Strategic Advisor [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

640,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | Outside Directors [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

120,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

120,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

$ 92,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)

$ 3.72

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Employee Stock Option [Member] | Three Outside Directors [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

40,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 4.88

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Nonqualified Stock Option [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

60,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 5.56

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

$ 34,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)

$ 3.72

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Nonqualified Stock Option [Member] | Chairmans Compensation [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

30,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Nonqualified Stock Option [Member] | Directors Additional Compensation Service [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

30,000

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] | Re-Priced Options [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

2,184,125

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)

$ 2.575

Share-based Compensation (in Dollars)

$ 297,000

Common Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Proceeds from Issuance of Common Stock (in Dollars)

$ 6,400

Stock Issued During Period, Shares, New Issues

640,000

Share Price (in Dollars per share)

$ 6.25

Stock Issued During Period, Shares, Issued for Services

11,600

12,400

Stock Issued During Period, Shares, Conversion of Convertible Securities

330,683

Warrant [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

320,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 10

Class of Warrant or Right, Expiration Period

5 years

Cancellation of Warrants, Exercise Price (in Dollars per share)

$ 0.025

Preferred Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Preferred Stock, Shares Authorized

19,860

19,860

200,000

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$ 100

$ 100

$ 100

Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Common Stock, Anti-dilution Threshold Price (in Dollars per share) (in Dollars per share)

3.55

Preferred Stock, Shares Authorized

140

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$ 100

Stock Issued During Period, Shares, Conversion of Convertible Securities

140

Convertible Preferred Stock, Shares Converted, Initial Stated Value (in Dollars per share) (in Dollars per share)

1,000

Convertible Preferred Stock, Initial Conversion Price (in Dollars per share) (in Dollars per share)

$ 4.73

Common Stock, Shares Outstanding, Maximum Ownership Percentage

4.99%

Convertible Preferred Stock, Mandatory Conversion, Measurment Period

the average of the high and low trading prices of the Company’s common stock for any 10 out of 20 consecutive trading days

Convertible Preferred Stock,Mandatory Conversion, Threshold Trading Volume Percentage

50.00%

Convertible Preferred Stock Redemption, Notice Period

60 days

Conertible Preferred Stock, Observer Designation, Notice Period

10 days

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - Information regarding the 2003 and 2010 Share Plan - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
2003 Share Plan [Member]
SHAREHOLDERS' EQUITY (Details) - Information regarding the 2003 and 2010 Share Plan [Line Items]
Options Outstanding, Shares	493,991	625,554
Options Outstanding, Weighted Average Exercise Price Per Share	$ 18	$ 18
Options Exercised, Shares	(4,000)	(17,400)
Options Exercised, Weighted Average Exercise Price Per Share	$ 2.58	$ 3.63
Options Forfeited, Shares	(123,771)	(114,163)
Options Forfeited, Weighted Average Exercise Price Per Share	$ 14.71	$ 19.75
Options Outstanding and Exercisable at October 31, 2015	366,200
Options Outstanding and Exercisable at October 31, 2015	$ 17.86
Options Outstanding and Exercisable at October 31, 2015	$ 61,665
Options Outstanding, Shares		493,991
Options Outstanding, Weighted Average Exercise Price Per Share		$ 18
2010 Share Plan [Member]
SHAREHOLDERS' EQUITY (Details) - Information regarding the 2003 and 2010 Share Plan [Line Items]
Options Outstanding, Shares	728,560	119,360
Options Outstanding, Weighted Average Exercise Price Per Share	$ 5.75	$ 6.13
Options Granted, Shares	60,400	612,400
Options Granted, Weighted Average Exercise Price Per Share	$ 2.91	$ 5.75
Options Exercised, Shares	(13,334)	(3,200)
Options Exercised, Weighted Average Exercise Price Per Share	$ 2.58	$ 4
Options Forfeited, Shares	(249,355)
Options Forfeited, Weighted Average Exercise Price Per Share	$ 6.24
Options Outstanding, Shares	526,271	728,560
Options Outstanding, Weighted Average Exercise Price Per Share	$ 3.33	$ 5.75
Options Outstanding, Aggregate Intrinsic Value	$ 471,292
Options Exercisable at October 31, 2015	406,149
Options Exercisable at October 31, 2015	$ 3.40
Options Exercisable at October 31, 2015	$ 342,572

SHAREHOLDERS' EQUITY (Details51

SHAREHOLDERS' EQUITY (Details) - Stock options outstanding and exercisable under 2003 share plan	12 Months Ended
	Oct. 31, 2015$ / sharesshares
Range Of Exercise Prices $1.79 To $9.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number | shares	73,880
Options Outstanding,Weighted Average Remaining Contractual Life (in years)	1 year 9 months
Options Outstanding, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 2.91
Range Of Exercise Prices $14.75 To $17.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number | shares	59,600
Options Outstanding,Weighted Average Remaining Contractual Life (in years)	1 year 120 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 16.75
Range Of Exercise Prices $18.75 To $23.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number | shares	192,720
Options Outstanding,Weighted Average Remaining Contractual Life (in years)	1 year 51 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 21.57
Range Of Exercise Prices $29.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number | shares	40,000
Options Outstanding,Weighted Average Remaining Contractual Life (in years)	1 year 292 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 29.25

SHAREHOLDERS' EQUITY (Details52

SHAREHOLDERS' EQUITY (Details) - Stock options outstanding under 2010 Share Plan - Range of Exercise Prices $2.58 To $9.25 [Member] - 2010 Share Plan [Member]	12 Months Ended
	Oct. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number | shares	526,271
Options Outstanding, Weighted Average Remaining Contractual Life	6 years 357 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 3.33
Options Exercisable, Number | shares	406,149
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 208 days
Options Exercisable,Weighted Average Exercise Price | $ / shares	$ 3.40

SHAREHOLDERS' EQUITY (Details53

SHAREHOLDERS' EQUITY (Details) - Stock options granted not under 2003 Share Plan and 2010 Share Plan - Range of Exercise Prices $2.58 To $5.56 [Member] - Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]	12 Months Ended
	Oct. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Shares | shares	1,780,000
Options Outstanding, Weighted Average Remaining Contractual Life	6 years 277 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 2.71

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	12 Months Ended
	Oct. 31, 2015USD ($)m²	Oct. 31, 2014USD ($)
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Patent Acquisition Obligations Discounted, Present Value	$ 3,688,000
Interest Expense, Patent Acquisition Obligations	452,000	$ 386,000
Operating Leases, Future Minimum Payments Due	44,000
Operating Leases, Rent Expense	$ 100,000	$ 109,000
Property Available for Operating Lease [Member] | Los Angeles California [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Area of Land (in Square Meters) | m²	3,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforward and Tax Credit Carryforward Expiration, Date Range	expiring at various dates between 2016 and 2035
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	(34.00%)	(34.00%)
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%
Federal Corporate Taxable [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 75,642,000
Tax Credit Carryforward, Amount	1,110,000
New York State [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	72,505,000
Tax Credit Carryforward, Amount	11,000
California State [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 2,803,000

INCOME TAXES (Details) - Income

INCOME TAXES (Details) - Income tax provision (benefit) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Federal:
Current
Deferred	$ (487,000)	$ (1,606,000)
State:
Current
Deferred	$ (120,000)	$ (1,000)
Adjustment to valuation allowance related to net deferred tax assets	$ 607,000	$ 1,607,000
Income tax provision (benefit)

INCOME TAXES (Details) - The ta

INCOME TAXES (Details) - The tax effects of temporary differences of the deferred tax - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Long-term deferred tax assets:
Federal and state NOL and tax credit carryforwards	$ 31,261,000	$ 31,864,000
Deferred compensation	6,522,000	$ 5,437,000
Intangibles	483,000
Other	282,000	$ 359,000
Subtotal	38,548,000	37,660,000
Less: valuation allowance	$ (38,548,000)	$ (37,660,000)
Deferred tax asset, net

INCOME TAXES (Details) - Reconc

INCOME TAXES (Details) - Reconciliation of income taxes at the Federal statutory tax rate - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Reconciliation of income taxes at the Federal statutory tax rate [Abstract]
Income tax benefit at U.S. Federal statutory income Tax rate	$ (469,000)	$ (3,266,000)
Income tax benefit at U.S. Federal statutory income Tax rate	(34.00%)	(34.00%)
State income taxes	$ (117,000)	$ (6,000)
State income taxes	(8.50%)	(0.06%)
Permanent differences	$ 1,000	$ 1,529,000
Permanent differences	0.10%	15.92%
Expiring net operating losses, credits and other	$ (22,000)	$ 115,000
Expiring net operating losses, credits and other	(1.60%)	1.19%
Foreign rate difference on impairment		$ 21,000
Foreign rate difference on impairment	0.00%	0.22%
Change in valuation allowance	$ 607,000	$ 1,607,000
Change in valuation allowance	44.00%	16.73%
Income tax provision
Income tax provision	0.00%	0.00%